117 results on '"Guinovart, C."'
Search Results
2. Sleeping arrangements and mass distribution of bed nets in six districts in central and northern Mozambique
- Author
-
Plucinski, M. M., Chicuecue, S., Macete, E., Chambe, G. A., Muguande, O., Matsinhe, G., Colborn, J., Yoon, S. S., Doyle, T. J., Kachur, S. P., Aide, P., Alonso, P. L., Guinovart, C., and Morgan, J.
- Published
- 2015
- Full Text
- View/download PDF
3. Immune responses to Plasmodium falciparum in a cohort of Mozambican pregnant women and their children in relation to age, exposure and clinical outcomes
- Author
-
Dobaño, C., Mayor, A. G., Nhabomba, A., Manaca, N., Guinovart, C., Berthoud, T., Quinto, L., Aguilar, R., Barbosa, A., Jimenez, A., Bassat, Q., Aponte, J. J., Chitnis, C., Doolan, D. L., and Alonso, P. L.
- Published
- 2011
4. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique
- Author
-
Macete, E., Aponte, J. J., Guinovart, C., Sacarlal, J., Ofori-Anyinam, O., Mandomando, I., Espasa, M., Bevilacqua, C., Leach, A., Dubois, M. C., Heppner, D. G., Tello, L., Milman, J., Cohen, J., Dubovsky, F., Tornieporth, N., Thompson, R., and Alonso, P. L.
- Published
- 2007
5. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination.
- Author
-
Greenhouse, B, Daily, J, Guinovart, C, Goncalves, B, Beeson, J, Bell, D, Chang, MA, Cohen, JM, Ding, X, Domingo, G, Eisele, TP, Lammie, PJ, Mayor, A, Merienne, N, Monteiro, W, Painter, J, Rodriguez, I, White, M, Drakeley, C, Mueller, I, Malaria Serology Convening, Greenhouse, B, Daily, J, Guinovart, C, Goncalves, B, Beeson, J, Bell, D, Chang, MA, Cohen, JM, Ding, X, Domingo, G, Eisele, TP, Lammie, PJ, Mayor, A, Merienne, N, Monteiro, W, Painter, J, Rodriguez, I, White, M, Drakeley, C, Mueller, I, and Malaria Serology Convening
- Abstract
Measurement of malaria specific antibody responses represents a practical and informative method for malaria control programs to assess recent exposure to infection. Technical advances in recombinant antigen production, serological screening platforms, and analytical methods have enabled the identification of several target antigens for laboratory based and point-of-contact tests. Questions remain as to how these serological assays can best be integrated into malaria surveillance activities to inform programmatic decision-making. This report synthesizes discussions from a convening at Institut Pasteur in Paris in June 2017 aimed at defining practical and informative use cases for serology applications and highlights five programmatic uses for serological assays including: documenting the absence of transmission; stratification of transmission; measuring the effect of interventions; informing a decentralized immediate response; and testing and treating P. vivax hypnozoite carriers.
- Published
- 2019
6. Cord Blood IL-12 Confers Protection to Clinical Malaria in Early Childhood Life
- Author
-
Song, Y., Aguilar, R., Guo, J., Manaca, M., Nhabomba, A., Berthoud, T., Khoo, S., Wiertsema, S., Barbosa, A., Quintó, L., Laing, I., Mayor, A., Guinovart, C., Alonso, P., Lesouëf, P., Dobaño, C., Zhang, Guicheng, Song, Y., Aguilar, R., Guo, J., Manaca, M., Nhabomba, A., Berthoud, T., Khoo, S., Wiertsema, S., Barbosa, A., Quintó, L., Laing, I., Mayor, A., Guinovart, C., Alonso, P., Lesouëf, P., Dobaño, C., and Zhang, Guicheng
- Abstract
Using a well-designed longitudinal cohort, we aimed to identify cytokines that were protective against malaria and to explore how they were influenced by genetic and immunological factors. 349 Mozambican pregnant women and their newborn babies were recruited and followed up for malaria outcomes until 24 months of age. Six Th1 cytokines in cord blood were screened for correlation with malaria incidence, of which IL-12 was selected for further analyses. We genotyped IL-12 polymorphisms in children/mothers and evaluated the genotype-phenotype associations and genetic effects on IL-12 levels. Maternal IL-12 concentrations were also investigated in relation to Plasmodium infections and cord blood IL-12 levels. Our data showed that high background IL-12 levels were prospectively associated with a low incidence of clinical malaria, while IL-12 production after parasite stimulation had the opposite effect on malaria incidence. IL-12 genotypes (IL-12b rs2288831/rs17860508) and the haplotype CGTTAGAG distribution were related to malaria susceptibility and background IL-12 levels. Maternal genotypes also exhibited an evident impact on host genotype-phenotype associations. Finally, a positive correlation in background IL-12 levels between maternal and cord blood was identified. Thus, cord blood background IL-12 concentrations are important for protecting children from clinical malaria, likely mediated by both genotypes (children&mothers) and maternal immunity.
- Published
- 2018
7. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
- Author
-
Vos, T, Barber, Rm, Bell, B, Bertozzi Villa, A, Biryukov, S, Bolliger, I, Charlson, F, Davis, A, Degenhardt, L, Dicker, D, Duan, L, Erskine, H, Feigin, Vl, Ferrari, Aj, Fitzmaurice, C, Fleming, T, Graetz, N, Guinovart, C, Haagsma, J, Hansen, Gm, Hanson, Sw, Heuton, Kr, Higashi, H, Kassebaum, N, Kyu, H, Laurie, E, Liang, X, Lofgren, K, Lozano, R, Macintyre, Mf, Moradi Lakeh, M, Naghavi, M, Nguyen, G, Odell, S, Ortblad, K, Roberts, Da, Roth, Ga, Sandar, L, Serina, Pt, Stanaway, Jd, Steiner, C, Thomas, B, Vollset, Se, Whiteford, H, Wolock, Tm, Ye, P, Zhou, M, Ãvila, Ma, Aasvang, Gm, Abbafati, C, Abbasoglu, Ozgoren, A, Abd Allah, F, Abdel, Aziz, Abera, Sf, Aboyans, V, Abraham, Jp, Abraham, B, Abubakar, I, Abu Raddad, Lj, Abu Rmeileh, Nm, Aburto, Tc, Achoki, T, Ackerman, In, Adelekan, A, Ademi, Z, Adou, Ak, Adsuar, Jc, Arnlov, J, Agardh, Ee, Khabouri, Al, Alam, Ss, Alasfoor, D, Albittar, Mi, Alegretti, Ma, Aleman, Av, Alemu, Za, Alfonso Cristancho, R, Alhabib, S, Ali, R, Alla, F, Allebeck, P, Allen, Pj, Almazroa, Ma, Alsharif, U, Alvarez, E, Alvis, Guzman, Ameli, N, O, Amini, H, Ammar, W, Anderson, Bo, Anderson, Hr, Antonio, Ca, Anwari, P, Apfel, H, Arsenijevic, Vs, Artaman, A, Asghar, Rj, Assadi, R, Atkins, Ls, Atkinson, C, Badawi, A, Bahit, Mc, Bakfalouni, T, Balakrishnan, K, Balalla, S, Banerjee, A, Barker Collo, Sl, Barquera, S, Barregard, L, Barrero, Lh, Basu, S, Basu, A, Baxter, A, Beardsley, J, Bedi, N, Beghi, E, Bekele, T, Bell, Ml, Benjet, C, Bennett, Da, Bensenor, Im, Benzian, H, Bernabe, E, Beyene, Tj, Bhala, N, Bhalla, A, Bhutta, Z, Bienhoff, K, Bikbov, B, Bin, Abdulhak, Blore, Jd, Blyth, Fm, Bohensky, Ma, Bora, Basara, B, Borges, G, Bornstein, Nm, Bose, D, Boufous, S, Bourne, Rr, Boyers, Ln, Brainin, M, Brauer, M, Brayne, Ce, Brazinova, A, Breitborde, Nj, Brenner, H, Briggs, Ad, Brooks, Pm, Brown, J, Brugha, Ts, Buchbinder, R, Buckle, Gc, Bukhman, G, Bulloch, Ag, Burch, M, Burnett, R, Cardenas, R, Cabral, Nl, Campos, Nonato, Campuzano, Ir, Carapetis, Jc, Carpenter, Do, Caso, V, Castaneda Orjuela, Ca, Catala Lopez, F, Chadha, Vk, Chang, Jc, Chen, H, Chen, W, Chiang, Pp, Chimed Ochir, O, Chowdhury, R, Christensen, H, Christophi, Ca, Chugh, Ss, Cirillo, Massimo, Coggeshall, M, Cohen, A, Colistro, V, Colquhoun, Sm, Contreras, Ag, Cooper, Lt, Cooper, C, Cooperrider, K, Coresh, J, Cortinovis, M, Criqui, Mh, Crump, Ja, Cuevas Nasu, L, Dandona, R, Dandona, L, Dansereau, E, Dantes, Hg, Dargan, Pi, Davey, G, Davitoiu, Dv, Dayama, A, La, De, Cruz, Gongora, De, V, Vega, La, De, Sf, Leo, D, Del, Pozo, Cruz, Dellavalle, Rp, Deribe, K, Derrett, S, Des, Jarlais, Dessalegn, M, Deveber, Ga, Dharmaratne, Sd, Diaz Torne, C, Ding, El, Dokova, K, Dorsey, Er, Driscoll, Tr, Duber, H, Durrani, Am, Edmond, Km, Ellenbogen, Rg, Endres, M, Ermakov, Sp, Eshrati, B, Esteghamati, A, Estep, K, Fahimi, S, Farzadfar, F, Fay, Df, Felson, Dt, Fereshtehnejad, Sm, Fernandes, Jg, Ferri, Cp, Flaxman, A, Foigt, N, Foreman, Kj, Fowkes, Fg, Franklin, Rc, Furst, T, Futran, Nd, Gabbe, Bj, Gankpe, Fg, Garcia, Guerra, Geleijnse, Fa, Gessner, Bd, Gibney, Kb, Gillum, Rf, Ginawi, Ia, Giroud, M, Giussani, G, Goenka, S, Goginashvili, K, Gona, P, Gonzalez, De, Cosio, T, Gosselin, Ra, Gotay, Cc, Goto, A, Gouda, Hn, Guerrant, Rl, Gugnani, Hc, Gunnell, D, Gupta, R, Gutierrez, Ra, Hafezi Nejad, N, Hagan, H, Halasa, Y, Hamadeh, Rr, Hamavid, H, Hammami, M, Hankey, Gj, Hao, Y, Harb, Hl, Haro, Jm, Havmoeller, R, Hay, Rj, Hay, S, Hedayati, Mt, Heredia, Pi, Heydarpour, P, Hijar, M, Hoek, Hw, Hoffman, Hj, Hornberger, Jc, Hosgood, Hd, Hossain, M, Hotez, Pj, Hoy, Dg, Hsairi, M, Hu, H, Hu, G, Huang, Jj, Huang, C, Huiart, L, Husseini, A, Iannarone, M, Iburg, Km, Innos, K, Inoue, M, Jacobsen, Kh, Jassal, Sk, Jeemon, P, Jensen, Pn, Jha, V, Jiang, G, Jiang, Y, Jonas, Jb, Joseph, J, Juel, K, Kan, H, Karch, A, Karimkhani, C, Karthikeyan, G, Katz, R, Kaul, A, Kawakami, N, Kazi, Ds, Kemp, Ah, Kengne, Ap, Khader, Ys, Khalifa, Se, Khan, Ea, Khan, G, Khang, Yh, Khonelidze, I, Kieling, C, Kim, D, Kim, S, Kimokoti, Rw, Kinfu, Y, Kinge, Jm, Kissela, Bm, Kivipelto, M, Knibbs, L, Knudsen, Ak, Kokubo, Y, Kosen, S, Kramer, A, Kravchenko, M, Krishnamurthi, Rv, Krishnaswami, S, Kuate, Defo, Kucuk, B, Bicer, B, Kuipers, Ej, Kulkarni, Vs, Kumar, K, Kumar, Ga, Kwan, Gf, Lai, T, Lalloo, R, Lam, H, Lan, Q, Lansingh, Vc, Larson, H, Larsson, A, Lawrynowicz, Ae, Leasher, Jl, Lee, Jt, Leigh, J, Leung, R, Levi, M, Li, B, Li, Y, Liang, J, Lim, S, Lin, Hh, Lind, M, Lindsay, Mp, Lipshultz, Se, Liu, S, Lloyd, Bk, Lockett, Ohno, S, Logroscino, G, Looker, Kj, Lopez, Ad, Lopez Olmedo, N, Lortet Tieulent, J, Lotufo, Pa, Low, N, Lucas, Rm, Lunevicius, R, Lyons, Ra, Ma, J, Ma, S, Mackay, Mt, Majdan, M, Malekzadeh, R, Mapoma, Cc, Marcenes, W, March, Lm, Margono, C, Marks, Gb, Marzan, Mb, Masci, Jr, Mason Jones, Aj, Matzopoulos, Rg, Mayosi, Bm, Mazorodze, Tt, Mcgill, Nw, Mcgrath, Jj, Mckee, M, Mclain, A, Mcmahon, Bj, Meaney, Pa, Mehndiratta, Mm, Mejia Rodriguez, F, Mekonnen, W, Melaku, Ya, Meltzer, M, Memish, Za, Mensah, G, Meretoja, A, Mhimbira, Fa, Micha, R, Miller, Tr, Mills, Ej, Mitchell, Pb, Mock, Cn, Moffitt, Te, Mohamed, Ibrahim, N, Mohammad, Ka, Mokdad, Ah, Mola, Gl, Monasta, L, Montico, M, Montine, Tj, Moore, Ar, Moran, Ae, Morawska, L, Mori, R, Moschandreas, J, Moturi, Wn, Moyer, M, Mozaffarian, D, Mueller, Uo, Mukaigawara, M, Murdoch, Me, Murray, J, Murthy, Ks, Naghavi, P, Nahas, Z, Naheed, A, Naidoo, Ks, Naldi, L, Nand, D, Nangia, V, Narayan, Km, Nash, D, Nejjari, C, Neupane, Sp, Newman, Lm, Newton, Cr, Ng, M, Ngalesoni, Fn, Nhung, Nt, Nisar, Mi, Nolte, S, Norheim, Of, Norman, Re, Norrving, B, Nyakarahuka, L, Ih, Oh, Ohkubo, T, Omer, Sb, Opio, Jn, Ortiz, A, Pandian, Jd, Panelo, Ci, Papachristou, C, Park, Ek, Parry, Cd, Caicedo, Aj, Patten, Sb, Paul, Vk, Pavlin, Bi, Pearce, N, Pedraza, Ls, Pellegrini, Ca, Pereira, Dm, Perez Ruiz, Fp, Perico, N, Pervaiz, A, Pesudovs, K, Peterson, Cb, Petzold, M, Phillips, Mr, Phillips, D, Phillips, B, Piel, Fb, Plass, D, Poenaru, D, Polanczyk, Gv, Polinder, S, Pope, Ca, Popova, S, Poulton, Rg, Pourmalek, F, Prabhakaran, D, Prasad, Nm, Qato, D, Quistberg, Da, Rafay, A, Rahimi, K, Rahimi Movaghar, V, Rahman, Su, Raju, M, Rakovac, I, Rana, Sm, Razavi, H, Refaat, A, Rehm, J, Remuzzi, G, Resnikoff, S, Ribeiro, Al, Riccio, Pm, Richardson, L, Richardus, Jh, Riederer, Am, Robinson, M, Roca, A, Rodriguez, A, Rojas Rueda, D, Ronfani, L, Rothenbacher, D, Roy, N, Ruhago, Gm, Sabin, N, Sacco, Rl, Ksoreide, K, Saha, S, Sahathevan, R, Sahraian, Ma, Sampson, U, Sanabria, Jr, Sanchez Riera, L, Santos, Is, Satpathy, M, Saunders, Je, Sawhney, M, Saylan, Mi, Scarborough, P, Schoettker, B, Schneider, Ij, Schwebel, Dc, Scott, Jg, Seedat, S, Sepanlou, Sg, Serdar, B, Servan Mori, Ee, Shackelford, K, Shaheen, A, Shahraz, S, Shamah, Levy, T, Shangguan, S, She, J, Sheikhbahaei, S, Shepard, Ds, Shi, P, Shibuya, K, Shinohara, Y, Shiri, R, Shishani, K, Shiue, I, Shrime, Mg, Sigfusdottir, Id, Silberberg, Dh, Simard, Ep, Sindi, S, Singh, Ja, Singh, L, Skirbekk, V, Sliwa, K, Soljak, M, Soneji, S, Soshnikov, Ss, Speyer, P, Sposato, La, Sreeramareddy, Ct, Stoeckl, H, Stathopoulou, Vk, Steckling, N, Stein, Mb, Stein, Dj, Steiner, Tj, Stewart, A, Stork, E, Stovner, Lj, Stroumpoulis, K, Sturua, L, Sunguya, Bf, Swaroop, M, Sykes, Bl, Tabb, Km, Takahashi, K, Tan, F, Tandon, N, Tanne, D, Tanner, M, Tavakkoli, M, Taylor, Hr, Ao, Te, Temesgen, Am, Ten, Have, M, Tenkorang, Ey, Terkawi, As, Theadom, Am, Thomas, E, Thorne Lyman, Al, Thrift, Ag, Tleyjeh, Im, Tonelli, M, Topouzis, F, Towbin, Ja, Toyoshima, H, Traebert, J, Tran, Bx, Trasande, L, Trillini, M, Truelsen, T, Trujillo, U, Tsilimbaris, M, Tuzcu, Em, Ukwaja, Kn, Undurraga, Ea, Uzun, Sb, Van, Brakel, Van, Wh, Vijver, De, Van, S, Dingenen, R, Van, Gool, Varakin, Yy, Vasankari, Tj, Vavilala, Ms, Veerman, Lj, Velasquez, Melendez, G, Venketasubramanian, N, Vijayakumar, L, Villalpando, S, Violante, Fs, Vlassov, Vv, Waller, S, Wallin, Mt, Wan, X, Wang, L, Wang, J, Wang, Y, Warouw, Ts, Weichenthal, S, Weiderpass, E, Weintraub, Rg, Werdecker, A, Wessells, Kr, Westerman, R, Wilkinson, Jd, Williams, Hc, Williams, Tn, Woldeyohannes, Sm, Wolfe, Cd, Wong, Jq, Wong, H, Woolf, Ad, Wright, Jl, Wurtz, B, Xu, G, Yang, G, Yano, Y, Yenesew, Ma, Yentur, Gk, Yip, P, Yonemoto, N, Yoon, Sj, Younis, M, Yu, C, Kim, Ky, Zaki, Mel, Zhang, Y, Zhao, Z, Zhao, Y, Zhu, J, Zonies, D, Zunt, Jr, Salomon, Ja, Murray, C. J., Vos, T, Barber, Rm, Bell, B, Bertozzi-Villa, A, Biryukov, S, Bolliger, I, Charlson, F, Davis, A, Degenhardt, L, Dicker, D, Duan, L, Erskine, H, Feigin, Vl, Ferrari, Aj, Fitzmaurice, C, Fleming, T, Graetz, N, Guinovart, C, Haagsma, J, Hansen, Gm, Hanson, Sw, Heuton, Kr, Higashi, H, Kassebaum, N, Kyu, H, Laurie ELiang, X, Lofgren, K, Lozano, R, Macintyre, Mf, Moradi-Lakeh, M, Naghavi, M, Nguyen, G, Odell, S, Ortblad, K, Roberts, Da, Roth, Ga, Sandar, L, Serina, Pt, Stanaway, Jd, Steiner, C, Thomas, B, Vollset, Se, Whiteford, H, Wolock, Tm, Ye, P, Zhou, M, Ãvila, Ma, Aasvang, Gm, Abbafati, C, Abbasoglu Ozgoren, A, Abd-Allah, F, Abdel Aziz MI, Abera, Sf, Aboyans, V, Abraham, Jp, Abraham, B, Abubakar, I, Abu-Raddad, Lj, Abu-Rmeileh, Nm, Aburto, Tc, Achoki TAckerman IN, Adelekan, A, Ademi, Z, Adou, Ak, Adsuar, Jc, Arnlov, J, Agardh, Ee, Al Khabouri MJ, Alam, S, Alasfoor, D, Albittar, Mi, Alegretti MAAleman AV, Alemu, Za, Alfonso-Cristancho, R, Alhabib, S, Ali, R, Alla, F, Allebeck, P, Allen, Pj, Almazroa, Ma, Alsharif, U, Alvarez, E, Alvis-Guzman NAmeli, O, Amini, H, Ammar, W, Anderson, Bo, Anderson, Hr, Antonio, Ca, Anwari, P, Apfel, H, Arsenijevic, V, Artaman, A, Asghar, Rj, Assadi, R, Atkins, L, Atkinson, C, Badawi, A, Bahit, Mc, Bakfalouni, T, Balakrishnan, K, Balalla, S, Banerjee, A, Barker-Collo, Sl, Barquera, S, Barregard, L, Barrero LHBasu, S, Basu, A, Baxter, A, Beardsley, J, Bedi, N, Beghi, E, Bekele, T, Bell, Ml, Benjet, C, Bennett, Da, Bensenor, Im, Benzian, H, Bernabe, E, Beyene TJBhala, N, Bhalla, A, Bhutta, Z, Bienhoff, K, Bikbov, B, Bin Abdulhak, A, Blore, Jd, Blyth, Fm, Bohensky, Ma, Bora Basara, B, Borges, G, Bornstein, Nm, Bose, D, Boufous, S, Bourne, Rr, Boyers, Ln, Brainin, M, Brauer, M, Brayne, Ce, Brazinova, A, Breitborde, Nj, Brenner, H, Briggs, Ad, Brooks, Pm, Brown JBrugha TS, Buchbinder, R, Buckle, Gc, Bukhman, G, Bulloch, Ag, Burch, M, Burnett, R, Cardenas, R, Cabral, Nl, Campos Nonato IR, Campuzano JCCarapetis JR, Carpenter, Do, Caso, V, Castaneda-Orjuela, Ca, Catala-Lopez, F, Chadha, Vk, Chang, Jc, Chen, H, Chen, W, Chiang, Pp, Chimed-Ochir, O, Chowdhury, R, Christensen, H, Christophi, Ca, Chugh, S, Cirillo, M, Coggeshall, M, Cohen, A, Colistro, V, Colquhoun, Sm, Contreras, Ag, Cooper LTCooper, C, Cooperrider, K, Coresh, J, Cortinovis, M, Criqui, Mh, Crump, Ja, Cuevas-Nasu, L, Dandona, R, Dandona, L, Dansereau, E, Dantes, Hg, Dargan, Pi, Davey, G, Davitoiu, Dv, Dayama, A, De la Cruz-Gongora, V, de la Vega SF, De Leo, D, del Pozo-Cruz, B, Dellavalle, Rp, Deribe, K, Derrett, S, Des Jarlais DC, Dessalegn, M, Deveber, Ga, Dharmaratne, Sd, Diaz-Torne, C, Ding, El, Dokova, K, Dorsey, Er, Driscoll, Tr, Duber, H, Durrani, Am, Edmond, Km, Ellenbogen, Rg, Endres, M, Ermakov, Sp, Eshrati, B, Esteghamati, A, Estep, K, Fahimi, S, Farzadfar, F, Fay, Df, Felson, Dt, Fereshtehnejad SMFernandes JG, Ferri, Cp, Flaxman, A, Foigt, N, Foreman, Kj, Fowkes, Fg, Franklin, Rc, Furst, T, Futran, Nd, Gabbe, Bj, Gankpe, Fg, Garcia-Guerra FAGeleijnse JM, Gessner, Bd, Gibney, Kb, Gillum, Rf, Ginawi, Ia, Giroud, M, Giussani, G, Goenka, S, Goginashvili, K, Gona, P, Gonzalez de Cosio TGosselin RA, Gotay, Cc, Goto, A, Gouda, Hn, Guerrant, Rl, Gugnani, Hc, Gunnell, D, Gupta, R, Gutierrez, Ra, Hafezi-Nejad, N, Hagan HHalasa, Y, Hamadeh, Rr, Hamavid, H, Hammami, M, Hankey, Gj, Hao, Y, Harb, Hl, Haro, Jm, Havmoeller, R, Hay, Rj, Hay, S, Hedayati, Mt, Heredia Pi IB, Heydarpour, P, Hijar, M, Hoek, Hw, Hoffman, Hj, Hornberger, Jc, Hosgood, Hd, Hossain, M, Hotez, Pj, Hoy, Dg, Hsairi, M, Hu, H, Hu, G, Huang JJHuang, C, Huiart, L, Husseini, A, Iannarone, M, Iburg, Km, Innos, K, Inoue, M, Jacobsen, Kh, Jassal, Sk, Jeemon, P, Jensen, Pn, Jha, V, Jiang, G, Jiang YJonas JB, Joseph, J, Juel, K, Kan, H, Karch, A, Karimkhani, C, Karthikeyan, G, Katz, R, Kaul, A, Kawakami, N, Kazi, D, Kemp, Ah, Kengne, Ap, Khader, Y, Khalifa, Se, Khan, Ea, Khan, G, Khang, Yh, Khonelidze, I, Kieling, C, Kim, D, Kim, S, Kimokoti, Rw, Kinfu, Y, Kinge, Jm, Kissela, Bm, Kivipelto MKnibbs, L, Knudsen, Ak, Kokubo, Y, Kosen, S, Kramer, A, Kravchenko, M, Krishnamurthi, Rv, Krishnaswami, S, Kuate Defo, B, Kucuk Bicer, B, Kuipers EJKulkarni VS, Kumar, K, Kumar, Ga, Kwan, Gf, Lai, T, Lalloo, R, Lam, H, Lan, Q, Lansingh, Vc, Larson, H, Larsson, A, Lawrynowicz, Ae, Leasher, Jl, Lee, Jt, Leigh, J, Leung, R, Levi, M, Li, B, Li, Y, Liang, J, Lim, S, Lin, Hh, Lind, M, Lindsay, Mp, Lipshultz, Se, Liu, S, Lloyd, Bk, Lockett Ohno, S, Logroscino, G, Looker, Kj, Lopez, Ad, Lopez-Olmedo, N, Lortet-Tieulent, J, Lotufo, Pa, Low, N, Lucas, Rm, Lunevicius, R, Lyons, Ra, Ma, J, Ma, S, Mackay MTMajdan, M, Malekzadeh, R, Mapoma, Cc, Marcenes, W, March, Lm, Margono, C, Marks, Gb, Marzan, Mb, Masci, Jr, Mason-Jones, Aj, Matzopoulos RGMayosi BM, Mazorodze, Tt, Mcgill, Nw, Mcgrath, Jj, Mckee, M, Mclain, A, Mcmahon, Bj, Meaney, Pa, Mehndiratta, Mm, Mejia-Rodriguez, F, Mekonnen, W, Melaku, Ya, Meltzer, M, Memish, Za, Mensah, G, Meretoja, A, Mhimbira, Fa, Micha, R, Miller, Tr, Mills, Ej, Mitchell, Pb, Mock, Cn, Moffitt TEMohamed Ibrahim, N, Mohammad, Ka, Mokdad, Ah, Mola, Gl, Monasta, L, Montico, M, Montine, Tj, Moore, Ar, Moran, Ae, Morawska, L, Mori RMoschandreas, J, Moturi, Wn, Moyer, M, Mozaffarian, D, Mueller, Uo, Mukaigawara, M, Murdoch, Me, Murray, J, Murthy, K, Naghavi, P, Nahas ZNaheed, A, Naidoo, K, Naldi, L, Nand, D, Nangia, V, Narayan, Km, Nash, D, Nejjari, C, Neupane, Sp, Newman, Lm, Newton, Cr, Ng, M, Ngalesoni FNNhung NT, Nisar, Mi, Nolte, S, Norheim, Of, Norman, Re, Norrving, B, Nyakarahuka, L, Oh, Ih, Ohkubo, T, Omer, Sb, Opio, Jn, Ortiz, A, Pandian JDPanelo CI, Papachristou, C, Park, Ek, Parry, Cd, Caicedo, Aj, Patten, Sb, Paul, Vk, Pavlin, Bi, Pearce, N, Pedraza, L, Pellegrini, Ca, Pereira, Dm, Perez-Ruiz, Fp, Perico, N, Pervaiz, A, Pesudovs, K, Peterson, Cb, Petzold, M, Phillips, Mr, Phillips, D, Phillips, B, Piel, Fb, Plass, D, Poenaru, D, Polanczyk GVPolinder, S, Pope, Ca, Popova, S, Poulton, Rg, Pourmalek, F, Prabhakaran, D, Prasad, Nm, Qato, D, Quistberg, Da, Rafay, A, Rahimi, K, Rahimi-Movaghar, V, Rahman, Su, Raju, M, Rakovac, I, Rana, Sm, Razavi, H, Refaat, A, Rehm, J, Remuzzi, G, Resnikoff, S, Ribeiro, Al, Riccio, Pm, Richardson, L, Richardus, Jh, Riederer, Am, Robinson, M, Roca, A, Rodriguez, A, Rojas-Rueda, D, Ronfani, L, Rothenbacher, D, Roy, N, Ruhago, Gm, Sabin, N, Sacco, Rl, Ksoreide, K, Saha, S, Sahathevan, R, Sahraian, Ma, Sampson, U, Sanabria, Jr, Sanchez-Riera, L, Santos, I, Satpathy, M, Saunders, Je, Sawhney, M, Saylan MIScarborough, P, Schoettker, B, Schneider, Ij, Schwebel, Dc, Scott, Jg, Seedat, S, Sepanlou, Sg, Serdar, B, Servan-Mori, Ee, Shackelford, K, Shaheen AShahraz, S, Shamah Levy, T, Shangguan, S, She, J, Sheikhbahaei, S, Shepard, D, Shi, P, Shibuya, K, Shinohara, Y, Shiri, R, Shishani, K, Shiue, I, Shrime, Mg, Sigfusdottir, Id, Silberberg, Dh, Simard, Ep, Sindi, S, Singh, Ja, Singh, L, Skirbekk, V, Sliwa, K, Soljak, M, Soneji, S, Soshnikov, S, Speyer PSposato LA, Sreeramareddy, Ct, Stoeckl, H, Stathopoulou, Vk, Steckling, N, Stein, Mb, Stein, Dj, Steiner, Tj, Stewart, A, Stork, E, Stovner LJStroumpoulis, K, Sturua, L, Sunguya, Bf, Swaroop, M, Sykes, Bl, Tabb, Km, Takahashi, K, Tan, F, Tandon, N, Tanne, D, Tanner, M, Tavakkoli, M, Taylor, Hr, Te Ao BJ, Temesgen, Am, Ten Have, M, Tenkorang, Ey, Terkawi, A, Theadom, Am, Thomas, E, Thorne-Lyman, Al, Thrift, Ag, Tleyjeh, Im, Tonelli, M, Topouzis, F, Towbin, Ja, Toyoshima, H, Traebert, J, Tran, Bx, Trasande, L, Trillini, M, Truelsen, T, Trujillo, U, Tsilimbaris, M, Tuzcu, Em, Ukwaja KNUndurraga EA, Uzun, Sb, van Brakel WH, van de Vijver, S, Van Dingenen, R, van Gool CH, Varakin, Yy, Vasankari, Tj, Vavilala, M, Veerman LJVelasquez-Melendez, G, Venketasubramanian, N, Vijayakumar, L, Villalpando, S, Violante, F, Vlassov, Vv, Waller, S, Wallin, Mt, Wan, X, Wang, L, Wang, J, Wang, Y, Warouw, T, Weichenthal, S, Weiderpass, E, Weintraub, Rg, Werdecker, A, Wessells, Kr, Westerman, R, Wilkinson, Jd, Williams HCWilliams TN, Woldeyohannes, Sm, Wolfe, Cd, Wong, Jq, Wong, H, Woolf, Ad, Wright, Jl, Wurtz, B, Xu, G, Yang, G, Yano, Y, Yenesew, Ma, Yentur GKYip, P, Yonemoto, N, Yoon, Sj, Younis, M, Yu, C, Kim, Ky, Zaki Mel, S, Zhang, Y, Zhao, Z, Zhao, Y, Zhu, J, Zonies, D, Zunt, Jr, Salomon, Ja, Murray, Cj., Vos, Theo, Barber, Ryan M., Bell, Brad, Bertozzi-Villa, Amelia, Biryukov, Stan, Bolliger, Ian, Charlson, Fiona, Davis, Adrian, Degenhardt, Louisa, Dicker, Daniel, Duan, Leilei, Erskine, Holly, Feigin, Valery L., Ferrari, Alize J., Fitzmaurice, Christina, Fleming, Thoma, Graetz, Nichola, Guinovart, Caterina, Haagsma, Juanita, Hansen, Gillian M., Hanson, Sarah Wulf, Heuton, Kyle R., Higashi, Hideki, Kassebaum, Nichola, Kyu, Hmwe, Laurie, Evan, Liang, Xiofeng, Lofgren, Katherine, Lozano, Rafael, Macintyre, Michael F., Moradi-Lakeh, Maziar, Naghavi, Mohsen, Nguyen, Grant, Odell, Shaun, Ortblad, Katrina, Roberts, David Allen, Roth, Gregory A., Sandar, Logan, Serina, Peter T., Stanaway, Jeffrey D., Steiner, Caitlyn, Thomas, Bernadette, Vollset, Stein Emil, Whiteford, Harvey, Wolock, Timothy M., Ye, Pengpeng, Zhou, Maigeng, Ãvila, Marco A., Aasvang, Gunn Marit, Abbafati, Cristiana, Ozgoren, Ayse Abbasoglu, Abd-Allah, Foad, Aziz, Muna I. Abdel, Abera, Semaw F., Aboyans, Victor, Abraham, Jerry P., Abraham, Biju, Abubakar, Ibrahim, Abu-Raddad, Laith J., Abu-Rmeileh, Niveen M.E., Aburto, Tania C., Achoki, Tom, Ackerman, Ilana N., Adelekan, Ademola, Ademi, Zanfina, Adou, Arsène K., Adsuar, Josef C., Arnlov, Johan, Agardh, Emilie E., Al Khabouri, Mazin J., Alam, Sayed Saidul, Alasfoor, Deena, Albittar, Mohammed I., Alegretti, Miguel A., Aleman, Alicia V., Alemu, Zewdie A., Alfonso-Cristancho, Rafael, Alhabib, Samia, Ali, Raghib, Alla, Francoi, Allebeck, Peter, Allen, Peter J., Almazroa, Mohammad Abdulaziz, Alsharif, Ubai, Alvarez, Elena, Alvis-Guzman, Nelson, Ameli, Omid, Amini, Heresh, Ammar, Walid, Anderson, Benjamin O., Anderson, H. Ro, Antonio, Carl Abelardo T., Anwari, Palwasha, Apfel, Henry, Arsenijevic, Valentain S. Arsic, Artaman, Al, Asghar, Rana J., Assadi, Reza, Atkins, Lydia S., Atkinson, Charle, Badawi, Alaa, Bahit, Maria C., Bakfalouni, Talal, Balakrishnan, Kalpana, Balalla, Shivanthi, Banerjee, Amitava, Barker-Collo, Suzanne L., Barquera, Simon, Barregard, Lar, Barrero, Lope H., Basu, Sanjay, Basu, Arindam, Baxter, Amanda, Beardsley, Justin, Bedi, Neeraj, Beghi, Ettore, Bekele, Tolesa, Bell, Michelle L., Benjet, Corina, Bennett, Derrick A., Bensenor, Isabela M., Benzian, Habib, Bernabe, Eduardo, Beyene, Tariku J., Bhala, Neeraj, Bhalla, Ashish, Bhutta, Zulfiqar, Bienhoff, Kelly, Bikbov, Bori, Abdulhak, Aref Bin, Blore, Jed D., Blyth, Fiona M., Bohensky, Megan A., Basara, Berrak Bora, Borges, Guilherme, Bornstein, Natan M., Bose, Dipan, Boufous, Soufiane, Bourne, Rupert R., Boyers, Lindsay N., Brainin, Michael, Brauer, Michael, Brayne, Carol E.G., Brazinova, Alexandra, Breitborde, Nicholas J.K., Brenner, Hermann, Briggs, Adam D.M., Brooks, Peter M., Brown, Jonathan, Brugha, Traolach S., Buchbinder, Rachelle, Buckle, Geoffrey C., Bukhman, Gene, Bulloch, Andrew G., Burch, Michael, Burnett, Richard, Cardenas, Rosario, Cabral, Norberto L., Campos-Nonato, Ismael R., Campuzano, Julio C., Carapetis, Jonathan R., Carpenter, David O., Caso, Valeria, Castaneda-Orjuela, Carlos A., Catala-Lopez, Ferran, Chadha, Vineet K., Chang, Jung-Chen, Chen, Honglei, Chen, Wanqing, Chiang, Peggy P., Chimed-Ochir, Odgerel, Chowdhury, Rajiv, Christensen, Hanne, Christophi, Costas A., Chugh, Sumeet S., Cirillo, Massimo, Coggeshall, Megan, Cohen, Aaron, Colistro, Valentina, Colquhoun, Samantha M., Contreras, Alejandra G., Cooper, Leslie T., Cooper, Cyru, Cooperrider, Kimberly, Coresh, Josef, Cortinovis, Monica, Criqui, Michael H., Crump, John A., Cuevas-Nasu, Lucia, Dandona, Rakhi, Dandona, Lalit, Dansereau, Emily, Dantes, Hector G., Dargan, Paul I., Davey, Gail, Davitoiu, Dragos V., Dayama, Anand, De La Cruz-Gongora, Vanessa, De La Vega, Shelley F., De Leo, Diego, Del Pozo-Cruz, Borja, Dellavalle, Robert P., Deribe, Kebede, Derrett, Sarah, Des Jarlais, Don C., Dessalegn, Muluken, Deveber, Gabrielle A., Dharmaratne, Samath D., Diaz-Torne, Cesar, Ding, Eric L., Dokova, Klara, Dorsey, E.R., Driscoll, Tim R., Duber, Herbert, Durrani, Adnan M., Edmond, Karen M., Ellenbogen, Richard G., Endres, Matthia, Ermakov, Sergey P., Eshrati, Babak, Esteghamati, Alireza, Estep, Kara, Fahimi, Saman, Farzadfar, Farshad, Fay, Derek F.J., Felson, David T., Fereshtehnejad, Seyed-Mohammad, Fernandes, Jefferson G., Ferri, Cluesa P., Flaxman, Abraham, Foigt, Nataliya, Foreman, Kyle J., Fowkes, F Gerry R., Franklin, Richard C., Furst, Thoma, Futran, Neal D., Gabbe, Belinda J., Gankpe, Fortune G., Garcia-Guerra, Francisco A., Geleijnse, Johanna M., Gessner, Bradford D., Gibney, Katherine B., Gillum, Richard F., Ginawi, Ibrahim A., Giroud, Maurice, Giussani, Giorgia, Goenka, Shifalika, Goginashvili, Ketevan, Gona, Philimon, De Cosio, Teresita Gonzalez, Gosselin, Richard A., Gotay, Carolyn C., Goto, Atsushi, Gouda, Hebe N., Guerrant, Richard L., Gugnani, Harish C., Gunnell, David, Gupta, Rajeev, Gupta, Rahul, Gutierrez, Reyna A., Hafezi-Nejad, Nima, Hagan, Holly, Halasa, Yara, Hamadeh, Randah R., Hamavid, Hannah, Hammami, Mouhanad, Hankey, Graeme J., Hao, Yuantao, Harb, Hilda L., Haro, Josep Maria, Havmoeller, Rasmu, Hay, Roderick J., Hay, Simon, Hedayati, Mohammad T., Pi, Ileana B. Heredia, Heydarpour, Pouria, Hijar, Martha, Hoek, Hans W., Hoffman, Howard J., Hornberger, John C., Hosgood, H. Dean, Hossain, Mazeda, Hotez, Peter J., Hoy, Damian G., Hsairi, Mohamed, Hu, Howard, Hu, Guoqing, Huang, John J., Huang, Cheng, Huiart, Laetitia, Husseini, Abdullatif, Iannarone, Marissa, Iburg, Kim M., Innos, Kaire, Inoue, Manami, Jacobsen, Kathryn H., Jassal, Simerjot K., Jeemon, Panniyammakal, Jensen, Paul N., Jha, Vivekanand, Jiang, Guohong, Jiang, Ying, Jonas, Jost B., Joseph, Jonathan, Juel, Knud, Kan, Haidong, Karch, Andre, Karimkhani, Chante, Karthikeyan, Ganesan, Katz, Ronit, Kaul, Anil, Kawakami, Norito, Kazi, Dhruv S., Kemp, Andrew H., Kengne, Andre P., Khader, Yousef S., Khalifa, Shams Eldin A.H., Khan, Ejaz A., Khan, Gulfaraz, Khang, Young-Ho, Khonelidze, Irma, Kieling, Christian, Kim, Daniel, Kim, Sungroul, Kimokoti, Ruth W., Kinfu, Yohanne, Kinge, Jonas M., Kissela, Brett M., Kivipelto, Miia, Knibbs, Luke, Knudsen, Ann Kristin, Kokubo, Yoshihiro, Kosen, Soewarta, Kramer, Alexander, Kravchenko, Michael, Krishnamurthi, Rita V., Krishnaswami, Sanjay, Defo, Barthelemy Kuate, Bicer, Burcu Kucuk, Kuipers, Ernst J., Kulkarni, Veena S., Kumar, Kaushalendra, Kumar, G Anil, Kwan, Gene F., Lai, Taavi, Lalloo, Ratilal, Lam, Hilton, Lan, Qing, Lansingh, Van C., Larson, Heidi, Larsson, Ander, Lawrynowicz, Alicia E.B., Leasher, Janet L., Lee, Jong-Tae, Leigh, Jame, Leung, Ricky, Levi, Miriam, Li, Bin, Li, Yichong, Li, Yongmei, Liang, Juan, Lim, Stephen, Lin, Hsien-Ho, Lind, Margaret, Lindsay, M Patrice, Lipshultz, Steven E., Liu, Shiwei, Lloyd, Belinda K., Ohno, Summer Lockett, Logroscino, Giancarlo, Looker, Katharine J., Lopez, Alan D., Lopez-Olmedo, Nancy, Lortet-Tieulent, Joannie, Lotufo, Paulo A., Low, Nicola, Lucas, Robyn M., Lunevicius, Raimunda, Lyons, Ronan A., Ma, Jixiang, Ma, Stefan, Mackay, Mark T., Majdan, Marek, Malekzadeh, Reza, Mapoma, Christopher C., Marcenes, Wagner, March, Lyn M., Margono, Chri, Marks, Guy B., Marzan, Melvin B., Masci, Joseph R., Mason-Jones, Amanda J., Matzopoulos, Richard G., Mayosi, Bongani M., Mazorodze, Tasara T., Mcgill, Neil W., Mcgrath, John J., Mckee, Martin, Mclain, Abby, Mcmahon, Brian J., Meaney, Peter A., Mehndiratta, Man Mohan, Mejia-Rodriguez, Fabiola, Mekonnen, Wubegzier, Melaku, Yohannes A., Meltzer, Michele, Memish, Ziad A., Mensah, George, Meretoja, Atte, Mhimbira, Francis A., Micha, Renata, Miller, Ted R., Mills, Edward J., Mitchell, Philip B., Mock, Charles N., Moffitt, Terrie E., Ibrahim, Norlinah Mohamed, Mohammad, Karzan A., Mokdad, Ali H., Mola, Glen L., Monasta, Lorenzo, Montico, Marcella, Montine, Thomas J., Moore, Ami R., Moran, Andrew E., Morawska, Lidia, Mori, Rintaro, Moschandreas, Joanna, Moturi, Wilkister N., Moyer, Madeline, Mozaffarian, Dariush, Mueller, Ulrich O., Mukaigawara, Mitsuru, Murdoch, Michele E., Murray, Joseph, Murthy, Kinnari S., Naghavi, Paria, Nahas, Ziad, Naheed, Aliya, Naidoo, Kovin S., Naldi, Luigi, Nand, Devina, Nangia, Vinay, Narayan, K.M. Venkat, Nash, Deni, Nejjari, Chakib, Neupane, Sudan P., Newman, Lori M., Newton, Charles R., Ng, Marie, Ngalesoni, Frida N., Nhung, Nguyen T., Nisar, Muhammad I., Nolte, Sandra, Norheim, Ole F., Norman, Rosana E., Norrving, Bo, Nyakarahuka, Luke, Oh, In Hwan, Ohkubo, Takayoshi, Omer, Saad B., Opio, John Nelson, Ortiz, Alberto, Pandian, Jeyaraj D., Panelo, Carlo Irwin A., Papachristou, Christina, Park, Eun-Kee, Parry, Charles D., Caicedo, Angel J. Paternina, Patten, Scott B., Paul, Vinod K., Pavlin, Boris I., Pearce, Neil, Pedraza, Lilia S., Pellegrini, Carlos A., Pereira, David M., Perez-Ruiz, Fernando P., Perico, Norberto, Pervaiz, Aslam, Pesudovs, Konrad, Peterson, Carrie B., Petzold, Max, Phillips, Michael R., Phillips, David, Phillips, Bryan, Piel, Frederic B., Plass, Dietrich, Poenaru, Dan, Polanczyk, Guilherme V., Polinder, Suzanne, Pope, C.A., Popova, Svetlana, Poulton, Richie G., Pourmalek, Farshad, Prabhakaran, Dorairaj, Prasad, Noela M., Qato, Dima, Quistberg, D.A., Rafay, Anwar, Rahimi, Kazem, Rahimi-Movaghar, Vafa, Rahman, Sajjad Ur, Raju, Murugesan, Rakovac, Ivo, Rana, Saleem M., Razavi, Homie, Refaat, Amany, Rehm, Jurgen, Remuzzi, Giuseppe, Resnikoff, Serge, Ribeiro, Antonio L., Riccio, Patricia M., Richardson, Lee, Richardus, Jan Hendrik, Riederer, Anne M., Robinson, Margot, Roca, Anna, Rodriguez, Alina, Rojas-Rueda, David, Ronfani, Luca, Rothenbacher, Dietrich, Roy, Nobhojit, Ruhago, George M., Sabin, Nsanzimana, Sacco, Ralph L., Ksoreide, Kjetil, Saha, Sukanta, Sahathevan, Ramesh, Sahraian, Mohammad Ali, Sampson, Uchechukwu, Sanabria, Juan R., Sanchez-Riera, Lidia, Santos, Itamar S., Satpathy, Maheswar, Saunders, James E., Sawhney, Monika, Saylan, Mete I., Scarborough, Peter, Schoettker, Ben, Schneider, Ione J.C., Schwebel, David C., Scott, James G., Seedat, Soraya, Sepanlou, Sadaf G., Serdar, Berrin, Servan-Mori, Edson E., Shackelford, Katya, Shaheen, Amira, Shahraz, Saeid, Levy, Teresa Shamah, Shangguan, Siyi, She, Jun, Sheikhbahaei, Sara, Shepard, Donald S., Shi, Peilin, Shibuya, Kenji, Shinohara, Yukito, Shiri, Rahman, Shishani, Kawkab, Shiue, Ivy, Shrime, Mark G., Sigfusdottir, Inga D., Silberberg, Donald H., Simard, Edgar P., Sindi, Shireen, Singh, Jasvinder A., Singh, Lavanya, Skirbekk, Vegard, Sliwa, Karen, Soljak, Michael, Soneji, Samir, Soshnikov, Sergey S., Speyer, Peter, Sposato, Luciano A., Sreeramareddy, Chandrashekhar T., Stoeckl, Heidi, Stathopoulou, Vasiliki Kalliopi, Steckling, Nadine, Stein, Murray B., Stein, Dan J., Steiner, Timothy J., Stewart, Andrea, Stork, Eden, Stovner, Lars J., Stroumpoulis, Konstantino, Sturua, Lela, Sunguya, Bruno F., Swaroop, Mamta, Sykes, Bryan L., Tabb, Karen M., Takahashi, Ken, Tan, Feng, Tandon, Nikhil, Tanne, David, Tanner, Marcel, Tavakkoli, Mohammad, Taylor, Hugh R., Te Ao, Braden J., Temesgen, Awoke Misganaw, Have, Margreet Ten, Tenkorang, Eric Yeboah, Terkawi, Abdullah Sulieman, Theadom, Alice M., Thomas, Elissa, Thorne-Lyman, Andrew L., Thrift, Amanda G., Tleyjeh, Imad M., Tonelli, Marcello, Topouzis, Foti, Towbin, Jeffrey A., Toyoshima, Hideaki, Traebert, Jefferson, Tran, Bach X., Trasande, Leonardo, Trillini, Matia, Truelsen, Thoma, Trujillo, Ulise, Tsilimbaris, Miltiadi, Tuzcu, Emin M., Ukwaja, Kingsley N., Undurraga, Eduardo A., Uzun, Selen B., Van Brakel, Wim H., Van De Vijver, Steven, Dingenen, Rita Van, Van Gool, Coen H., Varakin, Yuri Y., Vasankari, Tommi J., Vavilala, Monica S., Veerman, Lennert J., Velasquez-Melendez, Gustavo, Venketasubramanian, Narayanaswamy, Vijayakumar, Lakshmi, Villalpando, Salvador, Violante, Francesco S., Vlassov, Vasiliy V., Waller, Stephen, Wallin, Mitchell T., Wan, Xia, Wang, Linhong, Wang, Jianli, Wang, Yanping, Warouw, Tati S., Weichenthal, Scott, Weiderpass, Elisabete, Weintraub, Robert G., Werdecker, Andrea, Wessells, K. Ryan, Westerman, Ronny, Wilkinson, James D., Williams, Hywel C., Williams, Thomas N., Woldeyohannes, Solomon M., Wolfe, Charles D.A., Wong, John Q., Wong, Haidong, Woolf, Anthony D., Wright, Jonathan L., Wurtz, Brittany, Xu, Gelin, Yang, Gonghuan, Yano, Yuichiro, Yenesew, Muluken A., Yentur, Gokalp K., Yip, Paul, Yonemoto, Naohiro, Yoon, Seok-Jun, Younis, Mustafa, Yu, Chuanhua, Kim, Kim Yun, Zaki, Maysaa El Sayed, Zhang, Yong, Zhao, Zheng, Zhao, Yong, Zhu, Jun, Zonies, David, Zunt, Joseph R., Salomon, Joshua A., Murray, Christopher J.L., Cell biology, Gastroenterology & Hepatology, Epidemiology, Health Technology Assessment (HTA), and Public Health
- Subjects
Male ,Gerontology ,Nutrition and Disease ,Epidemiology ,years lived with disability, Global burden of disease, acute and chronic diseases, countries ,Prevalence ,Disease ,Global Health ,Medical and Health Sciences ,Conduct disorder ,Otitis-media ,Cost of Illness ,Residence Characteristics ,Voeding en Ziekte ,80 and over ,Global health ,2.2 Factors relating to the physical environment ,2.1 Biological and endogenous factors ,countries ,Aetiology ,Child ,Aged, 80 and over ,Medicine(all) ,education.field_of_study ,ATTENTION-DEFICIT/HYPERACTIVITY DISORDER ,Incidence ,Mortality rate ,Incidence (epidemiology) ,Pain Research ,Neglected Diseases ,Alcohol dependence ,General Medicine ,Middle Aged ,Global burden of disease ,Global Burden of Disease Study 2013 Collaborators ,Mental Health ,Infectious Diseases ,Attention deficit/Hyperactivity disorder ,Burden of Illness ,Child, Preschool ,Acute Disease ,Female ,Life Sciences & Biomedicine ,Adult ,medicine.medical_specialty ,Adolescent ,GBD 2013 ,Population ,acute and chronic diseases ,Young Adult ,Mental-disorders ,Age Distribution ,Medicine, General & Internal ,Weights ,General & Internal Medicine ,medicine ,Humans ,Life Science ,Disabled Persons ,Sex Distribution ,Preschool ,education ,Developing Countries ,VLAG ,Aged ,Science & Technology ,business.industry ,Developed Countries ,Cutaneous Leishmaniasis ,Infant, Newborn ,Infant ,Health outcomes ,Newborn ,medicine.disease ,Comorbidity ,Brain Disorders ,years lived with disability ,Good Health and Well Being ,Disease, injury, incidence, prevalence, YLDs, GBD 2010 ,Chronic Disease ,Wounds and Injuries ,business ,2.4 Surveillance and distribution ,Iron-deficiency ,Demography - Abstract
Summary Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013. Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause and sequelae list, updated systematic reviews, use of detailed injury codes, improvements to the Bayesian meta-regression method (DisMod-MR), and use of severity splits for various causes. An index of data representativeness, showing data availability, was calculated for each cause and impairment during three periods globally and at the country level for 2013. In total, 35 620 distinct sources of data were used and documented to calculated estimates for 301 diseases and injuries and 2337 sequelae. The comorbidity simulation provides estimates for the number of sequelae, concurrently, by individuals by country, year, age, and sex. Disability weights were updated with the addition of new population-based survey data from four countries. Findings Disease and injury were highly prevalent; only a small fraction of individuals had no sequelae. Comorbidity rose substantially with age and in absolute terms from 1990 to 2013. Incidence of acute sequelae were predominantly infectious diseases and short-term injuries, with over 2 billion cases of upper respiratory infections and diarrhoeal disease episodes in 2013, with the notable exception of tooth pain due to permanent caries with more than 200 million incident cases in 2013. Conversely, leading chronic sequelae were largely attributable to non-communicable diseases, with prevalence estimates for asymptomatic permanent caries and tension-type headache of 2·4 billion and 1·6 billion, respectively. The distribution of the number of sequelae in populations varied widely across regions, with an expected relation between age and disease prevalence. YLDs for both sexes increased from 537·6 million in 1990 to 764·8 million in 2013 due to population growth and ageing, whereas the age-standardised rate decreased little from 114·87 per 1000 people to 110·31 per 1000 people between 1990 and 2013. Leading causes of YLDs included low back pain and major depressive disorder among the top ten causes of YLDs in every country. YLD rates per person, by major cause groups, indicated the main drivers of increases were due to musculoskeletal, mental, and substance use disorders, neurological disorders, and chronic respiratory diseases; however HIV/AIDS was a notable driver of increasing YLDs in sub-Saharan Africa. Also, the proportion of disability-adjusted life years due to YLDs increased globally from 21·1% in 1990 to 31·2% in 2013. Interpretation Ageing of the world's population is leading to a substantial increase in the numbers of individuals with sequelae of diseases and injuries. Rates of YLDs are declining much more slowly than mortality rates. The non-fatal dimensions of disease and injury will require more and more attention from health systems. The transition to non-fatal outcomes as the dominant source of burden of disease is occurring rapidly outside of sub-Saharan Africa. Our results can guide future health initiatives through examination of epidemiological trends and a better understanding of variation across countries. Funding Bill & Melinda Gates Foundation. Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013. Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause and sequelae list, updated systematic reviews, use of detailed injury codes, improvements to the Bayesian meta-regression method (DisMod-MR), and use of severity splits for various causes. An index of data representativeness, showing data availability, was calculated for each cause and impairment during three periods globally and at the country level for 2013. In total, 35 620 distinct sources of data were used and documented to calculated estimates for 301 diseases and injuries and 2337 sequelae. The comorbidity simulation provides estimates for the number of sequelae, concurrently, by individuals by country, year, age, and sex. Disability weights were updated with the addition of new population-based survey data from four countries. Findings Disease and injury were highly prevalent; only a small fraction of individuals had no sequelae. Comorbidity rose substantially with age and in absolute terms from 1990 to 2013. Incidence of acute sequelae were predominantly infectious diseases and short-term injuries, with over 2 billion cases of upper respiratory infections and diarrhoeal disease episodes in 2013, with the notable exception of tooth pain due to permanent caries with more than 200 million incident cases in 2013. Conversely, leading chronic sequelae were largely attributable to non-communicable diseases, with prevalence estimates for asymptomatic permanent caries and tension-type headache of 2·4 billion and 1·6 billion, respectively. The distribution of the number of sequelae in populations varied widely across regions, with an expected relation between age and disease prevalence. YLDs for both sexes increased from 537·6 million in 1990 to 764·8 million in 2013 due to population growth and ageing, whereas the age-standardised rate decreased little from 114·87 per 1000 people to 110·31 per 1000 people between 1990 and 2013. Leading causes of YLDs included low back pain and major depressive disorder among the top ten causes of YLDs in every country. YLD rates per person, by major cause groups, indicated the main drivers of increases were due to musculoskeletal, mental, and substance use disorders, neurological disorders, and chronic respiratory diseases; however HIV/AIDS was a notable driver of increasing YLDs in sub-Saharan Africa. Also, the proportion of disability-adjusted life years due to YLDs increased globally from 21·1% in 1990 to 31·2% in 2013. Interpretation Ageing of the world's population is leading to a substantial increase in the numbers of individuals with sequelae of diseases and injuries. Rates of YLDs are declining much more slowly than mortality rates. The non-fatal dimensions of disease and injury will require more and more attention from health systems. The transition to non-fatal outcomes as the dominant source of burden of disease is occurring rapidly outside of sub-Saharan Africa. Our results can guide future health initiatives through examination of epidemiological trends and a better understanding of variation across countries. Funding Bill & Melinda Gates Foundation.
- Published
- 2015
8. Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013 Findings From the Global Burden of Disease 2013 Study
- Author
-
Kyu H, Pinho C, Wagner J, Brown J, Bertozzi-Villa A, Charlson F, Coffeng L, Dandona L, Erskine H, Ferrari A, Fitzmaurice C, Fleming T, Forouzanfar M, Graetz N, Guinovart C, Haagsma J, Higashi H, Kassebaum N, Larson H, Lim S, Mokdad A, Moradi-Lakeh M, Odell S, Roth G, Serina P, Stanaway J, Misganaw A, Whiteford H, Wolock T, Hanson S, Abd-Allah F, Abera S, Abu-Raddad L, AlBuhairan F, Amare A, Antonio C, Artaman A, Barker-Collo S, Barrero L, Benjet C, Bensenor I, Bhutta Z, Bikbov B, Brazinova A, Campos-Nonato I, Castaneda-Orjuela C, Catala-Lopez F, Chowdhury R, Cooper C, Crump J, Dandona R, Degenhardt L, Dellavalle R, Dharmaratne S, Faraon E, Feigin V, Furst T, Geleijnse J, Gessner B, Gibney K, Goto A, Gunnell D, Hankey G, Hay R, Hornberger J, Hosgood H, Hu G, Jacobsen K, Jayaraman S, Jeemon P, Jonas J, Karch A, Kim D, Kim S, Kokubo Y, Defo B, Bicer B, Kumar G, Larsson A, Leasher J, Leung R, Li Y, Lipshultz S, Lopez A, Lotufo P, Lunevicius R, Lyons R, Majdan M, Malekzadeh R, Mashal T, Mason-Jones A, Melaku Y, Memish Z, Mendoza W, Miller T, Mock C, Murray J, Nolte S, Oh I, Olusanya B, Ortblad K, Park E, Caicedo A, Patten S, Patton G, Pereira D, Perico N, Piel F, Polinder S, Popova S, Pourmalek F, Quistberg D, Remuzzi G, Rodriguez A, Rojas-Rueda D, Rothenbacher D, Rothstein D, Sanabria J, Santos I, Schwebel D, Sepanlou S, Shaheen A, Shiri R, Shiue I, Skirbekk V, Sliwa K, Sreeramareddy C, Stein D, Steiner T, Stovner L, Sykes B, Tabb K, Terkawi A, Thomson A, Thorne-Lyman A, Towbin J, Ukwaja K, Vasankari T, Venketasubramanian N, Vlassov V, Vollset S, Weiderpass E, Weintraub R, Werdecker A, Wilkinson J, Woldeyohannes S, Wolfe C, Yano Y, Yip P, Yonemoto N, Yoon S, Younis M, Yu C, Zaki M, Naghavi M, Murray C, Vos T, and Global Burden Dis Pediat Collabora
- Published
- 2016
9. Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013 Findings From the Global Burden of Disease 2013 Study
- Author
-
Kyu, HH, Pinho, C, Wagner, JA, Brown, JC, Bertozzi-Villa, A, Charlson, FJ, Coffeng, LE, Dandona, L, Erskine, HE, Ferrari, AJ, Fitzmaurice, C, Fleming, TD, Forouzanfar, MH, Graetz, N, Guinovart, C, Haagsma, J, Higashi, H, Kassebaum, NJ, Larson, HJ, Lim, SS, Mokdad, AH, Moradi-Lakeh, M, Odell, SV, Roth, GA, Serina, PT, Stanaway, JD, Misganaw, A, Whiteford, HA, Wolock, TM, Hanson, SW, Abd-Allah, F, Abera, SF, Abu-Raddad, LJ, AlBuhairan, FS, Amare, AT, Antonio, CAT, Artaman, A, Barker-Collo, SL, Barrero, LH, Benjet, C, Bensenor, IM, Bhutta, ZA, Bikbov, B, Brazinova, A, Campos-Nonato, I, Castaneda-Orjuela, CA, Catala-Lopez, F, Chowdhury, R, Cooper, C, Crump, JA, Dandona, R, Degenhardt, L, Dellavalle, RP, Dharmaratne, SD, Faraon, EJA, Feigin, VL, Fuerst, T, Geleijnse, JM, Gessner, BD, Gibney, KB, Goto, A, Gunnell, D, Hankey, GJ, Hay, RJ, Hornberger, JC, Hosgood, HD, Hu, G, Jacobsen, KH, Jayaraman, SP, Jeemon, P, Jonas, JB, Karch, A, Kim, D, Kim, S, Kokubo, Y, Defo, BK, Bicer, BK, Kumar, GA, Larsson, A, Leasher, JL, Leung, R, Li, Y, Lipshultz, SE, Lopez, AD, Lotufo, PA, Lunevicius, R, Lyons, RA, Majdan, M, Malekzadeh, R, Mashal, T, Mason-Jones, AJ, Melaku, YA, Memish, ZA, Mendoza, W, Miller, TR, Mock, CN, Murray, J, Nolte, S, Oh, I-H, Olusanya, BO, Ortblad, KF, Park, E-K, Paternina Caicedo, AJ, Patten, SB, Patton, GC, Pereira, DM, Perico, N, Piel, FB, Polinder, S, Popova, S, Pourmalek, F, Quistberg, DA, Remuzzi, G, Rodriguez, A, Rojas-Rueda, D, Rothenbacher, D, Rothstein, DH, Sanabria, J, Santos, IS, Schwebel, DC, Sepanlou, SG, Shaheen, A, Shiri, R, Shiue, I, Skirbekk, V, Sliwa, K, Sreeramareddy, CT, Stein, DJ, Steiner, TJ, Stovner, LJ, Sykes, BL, Tabb, KM, Terkawi, AS, Thomson, AJ, Thorne-Lyman, AL, Towbin, JA, Ukwaja, KN, Vasankari, T, Venketasubramanian, N, Vlassov, VV, Vollset, SE, Weiderpass, E, Weintraub, RG, Werdecker, A, Wilkinson, JD, Woldeyohannes, SM, Wolfe, CDA, Yano, Y, Yip, P, Yonemoto, N, Yoon, S-J, Younis, MZ, Yu, C, Zaki, MES, Naghavi, M, Murray, CJL, Vos, T, Kyu, HH, Pinho, C, Wagner, JA, Brown, JC, Bertozzi-Villa, A, Charlson, FJ, Coffeng, LE, Dandona, L, Erskine, HE, Ferrari, AJ, Fitzmaurice, C, Fleming, TD, Forouzanfar, MH, Graetz, N, Guinovart, C, Haagsma, J, Higashi, H, Kassebaum, NJ, Larson, HJ, Lim, SS, Mokdad, AH, Moradi-Lakeh, M, Odell, SV, Roth, GA, Serina, PT, Stanaway, JD, Misganaw, A, Whiteford, HA, Wolock, TM, Hanson, SW, Abd-Allah, F, Abera, SF, Abu-Raddad, LJ, AlBuhairan, FS, Amare, AT, Antonio, CAT, Artaman, A, Barker-Collo, SL, Barrero, LH, Benjet, C, Bensenor, IM, Bhutta, ZA, Bikbov, B, Brazinova, A, Campos-Nonato, I, Castaneda-Orjuela, CA, Catala-Lopez, F, Chowdhury, R, Cooper, C, Crump, JA, Dandona, R, Degenhardt, L, Dellavalle, RP, Dharmaratne, SD, Faraon, EJA, Feigin, VL, Fuerst, T, Geleijnse, JM, Gessner, BD, Gibney, KB, Goto, A, Gunnell, D, Hankey, GJ, Hay, RJ, Hornberger, JC, Hosgood, HD, Hu, G, Jacobsen, KH, Jayaraman, SP, Jeemon, P, Jonas, JB, Karch, A, Kim, D, Kim, S, Kokubo, Y, Defo, BK, Bicer, BK, Kumar, GA, Larsson, A, Leasher, JL, Leung, R, Li, Y, Lipshultz, SE, Lopez, AD, Lotufo, PA, Lunevicius, R, Lyons, RA, Majdan, M, Malekzadeh, R, Mashal, T, Mason-Jones, AJ, Melaku, YA, Memish, ZA, Mendoza, W, Miller, TR, Mock, CN, Murray, J, Nolte, S, Oh, I-H, Olusanya, BO, Ortblad, KF, Park, E-K, Paternina Caicedo, AJ, Patten, SB, Patton, GC, Pereira, DM, Perico, N, Piel, FB, Polinder, S, Popova, S, Pourmalek, F, Quistberg, DA, Remuzzi, G, Rodriguez, A, Rojas-Rueda, D, Rothenbacher, D, Rothstein, DH, Sanabria, J, Santos, IS, Schwebel, DC, Sepanlou, SG, Shaheen, A, Shiri, R, Shiue, I, Skirbekk, V, Sliwa, K, Sreeramareddy, CT, Stein, DJ, Steiner, TJ, Stovner, LJ, Sykes, BL, Tabb, KM, Terkawi, AS, Thomson, AJ, Thorne-Lyman, AL, Towbin, JA, Ukwaja, KN, Vasankari, T, Venketasubramanian, N, Vlassov, VV, Vollset, SE, Weiderpass, E, Weintraub, RG, Werdecker, A, Wilkinson, JD, Woldeyohannes, SM, Wolfe, CDA, Yano, Y, Yip, P, Yonemoto, N, Yoon, S-J, Younis, MZ, Yu, C, Zaki, MES, Naghavi, M, Murray, CJL, and Vos, T
- Abstract
IMPORTANCE: The literature focuses on mortality among children younger than 5 years. Comparable information on nonfatal health outcomes among these children and the fatal and nonfatal burden of diseases and injuries among older children and adolescents is scarce. OBJECTIVE: To determine levels and trends in the fatal and nonfatal burden of diseases and injuries among younger children (aged <5 years), older children (aged 5-9 years), and adolescents (aged 10-19 years) between 1990 and 2013 in 188 countries from the Global Burden of Disease (GBD) 2013 study. EVIDENCE REVIEW: Data from vital registration, verbal autopsy studies, maternal and child death surveillance, and other sources covering 14,244 site-years (ie, years of cause of death data by geography) from 1980 through 2013 were used to estimate cause-specific mortality. Data from 35,620 epidemiological sources were used to estimate the prevalence of the diseases and sequelae in the GBD 2013 study. Cause-specific mortality for most causes was estimated using the Cause of Death Ensemble Model strategy. For some infectious diseases (eg, HIV infection/AIDS, measles, hepatitis B) where the disease process is complex or the cause of death data were insufficient or unavailable, we used natural history models. For most nonfatal health outcomes, DisMod-MR 2.0, a Bayesian metaregression tool, was used to meta-analyze the epidemiological data to generate prevalence estimates. FINDINGS: Of the 7.7 (95% uncertainty interval [UI], 7.4-8.1) million deaths among children and adolescents globally in 2013, 6.28 million occurred among younger children, 0.48 million among older children, and 0.97 million among adolescents. In 2013, the leading causes of death were lower respiratory tract infections among younger children (905.059 deaths; 95% UI, 810,304-998,125), diarrheal diseases among older children (38,325 deaths; 95% UI, 30,365-47,678), and road injuries among adolescents (115,186 deaths; 95% UI, 105,185-124,870). Iron defici
- Published
- 2016
10. Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study.
- Author
-
Global Burden of Disease Pediatrics Collaboration, Kyu, H., Pinho, C., Wagner, J., Brown, J., Bertozzi-Villa, A., Charlson, F., Coffeng, L., Dandona, L., Erskine, H., Ferrari, A., Fitzmaurice, C., Fleming, T., Forouzanfar, M., Graetz, N., Guinovart, C., Haagsma, J., Higashi, H., Kassebaum, N., Larson, H., Lim, S., Mokdad, A., Moradi-Lakeh, M., Odell, S., Roth, G., Serina, P., Stanaway, J., Misganaw, A., Whiteford, H., Wolock, T., Wulf Hanson, S., Abd-Allah, F., Abera, S., Abu-Raddad, L., AlBuhairan, F., Amare, A., Antonio, C., Artaman, A., Barker-Collo, S., Barrero, L., Benjet, C., Bensenor, I., Bhutta, Z., Bikbov, B., Brazinova, A., Campos-Nonato, I., Castañeda-Orjuela, C., Catalá-López, F., Chowdhury, R., Cooper, C., Crump, J., Dandona, R., Degenhardt, L., Dellavalle, R., Dharmaratne, S., Faraon, E., Feigin, V., Fürst, T., Geleijnse, J., Gessner, B., Gibney, K., Goto, A., Gunnell, D., Hankey, G., Hay, R., Hornberger, J., Hosgood, H., Hu, G., Jacobsen, K., Jayaraman, S., Jeemon, P., Jonas, J., Karch, A., Kim, D., Kim, S., Kokubo, Y., Kuate Defo, B., Kucuk Bicer, B., Kumar, G., Larsson, A., Leasher, J., Leung, R., Li, Y., Lipshultz, S., Lopez, A., Lotufo, P., Lunevicius, R., Lyons, R., Majdan, M., Malekzadeh, R., Mashal, T., Mason-Jones, A., Melaku, Y., Memish, Z., Mendoza, W., Miller, Ted, Mock, C., Murray, J., Nolte, S., Oh, I., Olusanya, B., Ortblad, K., Park, E., Paternina Caicedo, A., Patten, S., Patton, G., Pereira, D., Perico, N., Piel, F., Polinder, S., Popova, S., Pourmalek, F., Quistberg, D., Remuzzi, G., Rodriguez, A., Rojas-Rueda, D., Rothenbacher, D., Rothstein, D., Sanabria, J., Santos, I., Schwebel, D., Sepanlou, S., Shaheen, A., Shiri, R., Shiue, I., Skirbekk, V., Sliwa, K., Sreeramareddy, C., Stein, D., Steiner, T., Stovner, L., Sykes, B., Tabb, K., Terkawi, A., Thomson, A., Thorne-Lyman, A., Towbin, J., Ukwaja, K., Vasankari, T., Venketasubramanian, N., Vlassov, V., Vollset, S., Weiderpass, E., Weintraub, R., Werdecker, A., Wilkinson, J., Woldeyohannes, S., Wolfe, C., Yano, Y., Yip, P., Yonemoto, N., Yoon, S., Younis, M., Yu, C., El Sayed Zaki, M., Naghavi, M., Murray, C., Vos, T., Global Burden of Disease Pediatrics Collaboration, Kyu, H., Pinho, C., Wagner, J., Brown, J., Bertozzi-Villa, A., Charlson, F., Coffeng, L., Dandona, L., Erskine, H., Ferrari, A., Fitzmaurice, C., Fleming, T., Forouzanfar, M., Graetz, N., Guinovart, C., Haagsma, J., Higashi, H., Kassebaum, N., Larson, H., Lim, S., Mokdad, A., Moradi-Lakeh, M., Odell, S., Roth, G., Serina, P., Stanaway, J., Misganaw, A., Whiteford, H., Wolock, T., Wulf Hanson, S., Abd-Allah, F., Abera, S., Abu-Raddad, L., AlBuhairan, F., Amare, A., Antonio, C., Artaman, A., Barker-Collo, S., Barrero, L., Benjet, C., Bensenor, I., Bhutta, Z., Bikbov, B., Brazinova, A., Campos-Nonato, I., Castañeda-Orjuela, C., Catalá-López, F., Chowdhury, R., Cooper, C., Crump, J., Dandona, R., Degenhardt, L., Dellavalle, R., Dharmaratne, S., Faraon, E., Feigin, V., Fürst, T., Geleijnse, J., Gessner, B., Gibney, K., Goto, A., Gunnell, D., Hankey, G., Hay, R., Hornberger, J., Hosgood, H., Hu, G., Jacobsen, K., Jayaraman, S., Jeemon, P., Jonas, J., Karch, A., Kim, D., Kim, S., Kokubo, Y., Kuate Defo, B., Kucuk Bicer, B., Kumar, G., Larsson, A., Leasher, J., Leung, R., Li, Y., Lipshultz, S., Lopez, A., Lotufo, P., Lunevicius, R., Lyons, R., Majdan, M., Malekzadeh, R., Mashal, T., Mason-Jones, A., Melaku, Y., Memish, Z., Mendoza, W., Miller, Ted, Mock, C., Murray, J., Nolte, S., Oh, I., Olusanya, B., Ortblad, K., Park, E., Paternina Caicedo, A., Patten, S., Patton, G., Pereira, D., Perico, N., Piel, F., Polinder, S., Popova, S., Pourmalek, F., Quistberg, D., Remuzzi, G., Rodriguez, A., Rojas-Rueda, D., Rothenbacher, D., Rothstein, D., Sanabria, J., Santos, I., Schwebel, D., Sepanlou, S., Shaheen, A., Shiri, R., Shiue, I., Skirbekk, V., Sliwa, K., Sreeramareddy, C., Stein, D., Steiner, T., Stovner, L., Sykes, B., Tabb, K., Terkawi, A., Thomson, A., Thorne-Lyman, A., Towbin, J., Ukwaja, K., Vasankari, T., Venketasubramanian, N., Vlassov, V., Vollset, S., Weiderpass, E., Weintraub, R., Werdecker, A., Wilkinson, J., Woldeyohannes, S., Wolfe, C., Yano, Y., Yip, P., Yonemoto, N., Yoon, S., Younis, M., Yu, C., El Sayed Zaki, M., Naghavi, M., Murray, C., and Vos, T.
- Abstract
Importance: The literature focuses on mortality among children younger than 5 years. Comparable information on nonfatal health outcomes among these children and the fatal and nonfatal burden of diseases and injuries among older children and adolescents is scarce. Objective: To determine levels and trends in the fatal and nonfatal burden of diseases and injuries among younger children (aged <5 years), older children (aged 5-9 years), and adolescents (aged 10-19 years) between 1990 and 2013 in 188 countries from the Global Burden of Disease (GBD) 2013 study. Evidence Review: Data from vital registration, verbal autopsy studies, maternal and child death surveillance, and other sources covering 14 244 site-years (ie, years of cause of death data by geography) from 1980 through 2013 were used to estimate cause-specific mortality. Data from 35 620 epidemiological sources were used to estimate the prevalence of the diseases and sequelae in the GBD 2013 study. Cause-specific mortality for most causes was estimated using the Cause of Death Ensemble Model strategy. For some infectious diseases (eg, HIV infection/AIDS, measles, hepatitis B) where the disease process is complex or the cause of death data were insufficient or unavailable, we used natural history models. For most nonfatal health outcomes, DisMod-MR 2.0, a Bayesian metaregression tool, was used to meta-analyze the epidemiological data to generate prevalence estimates.Findings: Of the 7.7 (95% uncertainty interval [UI], 7.4-8.1) million deaths among children and adolescents globally in 2013, 6.28 million occurred among younger children, 0.48 million among older children, and 0.97 million among adolescents. In 2013, the leading causes of death were lower respiratory tract infections among younger children (905 059 deaths; 95% UI, 810 304-998 125), diarrheal diseases among older children (38 325 deaths; 95% UI, 30 365-47 678), and road injuries among adolescents (115 186 deaths; 95% UI, 105 185-124 870). Iron deficie
- Published
- 2016
11. Compliance with oral typhoid vaccine Ty21a in travellers
- Author
-
Pous, E., Bayas, J.M., Vilella, A., Guinovart, C., Muñoz, A., and Adell, C.
- Published
- 2003
- Full Text
- View/download PDF
12. A research agenda for malaria eradication: vaccines
- Author
-
Abdulla, S., Agre, P., Alonso, P.L., Arevalo-Herrera, M., Bassat, Q., Binka, F., Chitnis, C., Corradin, G., Cowman, A. F., Culpepper, J., Portillo, H. del, Dinglasan, R.R., Duffy, P., Gargallo, D., Greenwood, B.M., Guinovart, C., Hall, B.F., Herrera, S., Hoffman, S., Lanzavecchia, A., Leroy, O., Levine, M.M., Loucq, C., Mendis, K., Milman, J., Moorthy, V.S., Pleuschke, G., Plowe, C.V., Reed, S., Sauerwein, R.W., Saul, A., Schofield, L., Sinden, R.R., Stubbs, J., Villafana, T., Wirth, D., Yadav, P., Ballou, R., Brown, G., Birkett, A., Brandt, W., Brooks, A., Carter, T., Golden, A., Lee, C., Nunes, J., Puijalon, O., Raphael, T., Richards, H., Warren, C., and Woods, C.
- Subjects
parasitic diseases ,Pathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1] - Abstract
Contains fulltext : 97591.pdf (Publisher’s version ) (Open Access) Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. We introduce the concept of "vaccines that interrupt malaria transmission" (VIMT), which includes not only "classical" transmission-blocking vaccines that target the sexual and mosquito stages but also pre-erythrocytic and asexual stage vaccines that have an effect on transmission. VIMT may also include vaccines that target the vector to disrupt parasite development in the mosquito. Importantly, if eradication is to be achieved, malaria vaccine development efforts will need to target other malaria parasite species, especially Plasmodium vivax, where novel therapeutic vaccines against hypnozoites or preventive vaccines with effect against multiple stages could have enormous impact. A target product profile (TPP) for VIMT is proposed and a research agenda to address current knowledge gaps and develop tools necessary for design and development of VIMT is presented.
- Published
- 2011
13. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
- Author
-
Murray, C.J.L. (Christopher), Ortblad, K.F. (Katrina F), Guinovart, C. (Caterina), Lim, S.S. (Stephen), Wolock, T.M. (Timothy M), Roberts, D.A. (D Allen), Dansereau, E.A. (Emily A), Graetz, N. (Nicholas), Barber, R.M. (Ryan), Brown, J.C. (Jonathan C), Wang, H. (Haidong), Duber, H.C. (Herbert C), Naghavi, M. (Morteza), Dicker, D. (Daniel), Dandona, L. (Lalit), Salomon, J.A. (Joshua), Heuton, K.R. (Kyle R), Foreman, K. (Kyle), Phillips, D.E. (David E), Fleming, T.D. (Thomas D), Flaxman, A.D. (Abraham D), Phillips, B.K. (Bryan K), Johnson, E.M. (Elizabeth), Coggeshall, M.S. (Megan S), Abd-Allah, F. (Foad), Abera, S.F. (Semaw Ferede), Abraham, J.P. (Jerry), Abubakar, I. (Ibrahim), Abu-Raddad, L.J. (Laith J), Abu-Rmeileh, N.M. (Niveen Me), Achoki, T. (Tom), Adeyemo, A. (Adebowale), Adou, A.K. (Arsène Kouablan), Adsuar, J.C. (José C), Agardh, E.E. (Emilie Elisabet), Akena, D. (Dickens), Al Kahbouri, M.J. (Mazin J), Alasfoor, D. (Deena), Albittar, M.I. (Mohammed I), Alcalá-Cerra, G. (Gabriel), Alegretti, M.A. (Miguel Angel), Alemu, G. (Getnet), Alfonso-Cristancho, R. (Rafael), Alhabib, S. (Samia), Ali, R. (Raghib), Alla, F. (Francois), Allen, P.J. (Peter), Alsharif, U. (Ubai), Alvarez, E. (Elena), Alvis-Guzman, N. (Nelson), Amankwaa, A.A. (Adansi A), Amare, A.T. (Azmeraw T), Amini, H. (Hassan), Ammar, K.A., Anderson, B.O. (Benjamin), Antonio, C.A.T. (Carl Abelardo T), Anwari, P. (Palwasha), Ärnlöv, J. (Johan), Arsenijevic, V.S.A. (Valentina S Arsic), Artaman, A. (Ali), Asghar, R.J. (Rana J), Assadi, R. (Reza), Atkins, L.S. (Lydia S), Badawi, A.F. (Alaa), Banerjee, A. (Amitava), Basu, S. (Saonli), Beardsley, J. (Justin), Bekele, T. (Tolesa), Bell, M.L. (Michelle Lee), Bernabe, E. (Eduardo), Beyene, T.J. (Tariku Jibat), Bhala, N. (Neeraj), Bhalla, P.L. (Pankaj), Bhutta, Z.A. (Zulfiqar A), Abdulhak, A.B. (Aref Bin), Binagwaho, A. (Agnes), Blore, J.D. (Jed D), Bose, D. (Dipan), Brainin, M. (Michael), Breitborde, N. (Nicholas), Castañeda-Orjuela, C.A. (Carlos A), Catalá-López, F. (Ferrán), Chadha, D., Chang, J.-C. (Jung-Chen), Chiang, Y.T., Chuang, T.-W. (Ting-Wu), Colomar, M. (Mercedes), Cooper Jr., L.T. (Leslie Trumbull), Cooper, C. (Charles), Courville, K.J. (Karen J), Cowie, M.R. (Martin R.), Criqui, M. (Michael), Dandona, R. (Rakhi), Dayama, A. (Anand), Leo, D. (Diego) de, Degenhardt, F., Del Pozo-Cruz, B. (Borja), Deribe, K. (Kebede), Des Jarlais, D.C. (Don C), Dessalegn, M. (Muluken), Dharmaratne, S.D. (Samath D), Dilmen, U. (Uǧur), Ding, E.L. (Eric), Driscoll, J.M., Durrani, Z., Ellenbogen, R.G. (Richard G), Ermakov, S. (Sergey), Esteghamati, A. (Alireza), Faraon, E.J.A. (Emerito Jose A), Farzadfar, F. (Farshad), Fereshtehnejad, S.-M. (Seyed-Mohammad), Fijabi, D.O. (Daniel Obadare), Forouzanfar, M.H. (Mohammad H), Fra.Paleo, U. (Urbano), Gaffikin, L. (Lynne), Gamkrelidze, A. (Amiran), Gankpé, F.G. (Fortuné Gbètoho), Geleijnse, J.M. (Marianne), Gessner, B.D. (Bradford D), Gibney, K.B. (Katherine B), Ginawi, I.A.M. (Ibrahim Abdelmageem Mohamed), Glaser, E.L. (Elizabeth L), Gona, P. (Philimon), Goto, A. (Akimoto), Gouda, H.N. (Hebe N), Gugnani, H.C. (Harish Chander), Gupta, R. (Rajeev), Hafezi-Nejad, N. (Nima), Hamadeh, R.R. (Randah Ribhi), Hammami, M. (Mouhanad), Hankey, G.J. (Graeme), Harb, H.L. (Hilda L), Haro, J.M. (Josep Maria), Havmoeller, R. (Rasmus), Hay, S.I. (Simon I), Hedayati, M.T. (Mohammad T), Pi, I.B.H. (Ileana B Heredia), Hoek, H.W. (Hans), Hornberger, J.C. (John C), Hosgood, H.D. (H Dean), Hotez, P.J. (Peter), Hoy, D.G. (Damian G), Huang, J. (Jian), Iburg, K.M. (Kim M), Idrisov, B.T. (Bulat T), Innos, K. (Kaire), Jacobsen, K.H. (Kathryn H), Jeemon, P. (Panniyammakal), Jensen, P.N. (Paul N), Jha, V. (Vivekanand), Jiang, G. (Guohong), Jonas, J.B., Juel, K. (Knud), Kan, H. (Haidong), Kankindi, I. (Ida), Karam, V. (Vincent), Karch, F. (Francois), Karema, C.K. (Corine Kakizi), Kaul, A. (Anil), Kawakami, N. (Norito), Kazi, D.S. (Dhruv S), Kemp, A.H. (Andrew H), Kengne, A.P. (Andre Pascal), Keren, A. (Andre), Kereselidze, M. (Maia), Khader, Y.S. (Yousef Saleh), Khalifa, S.E.A.H. (Shams Eldin Ali Hassan), Khan, E.A. (Ejaz Ahmed), Khang, Y.-H. (Young-Ho), Khonelidze, I. (Irma), Kinfu, Y. (Yohannes), Kinge, J.M. (Jonas M), Knibbs, L. (Luke), Kokubo, Y. (Yoshihiro), Kosen, S. (Soewarta), Defo, B.K. (Barthelemy Kuate), Kulkarni, V.S. (Veena S), Kulkarni, C. (Chanda), Kumar, K. (Kuldeep), Kumar, R.B. (Ravi B), Kumar, G.A. (G Anil), Kwan, G.F. (Gene F), Lai, T. (Taavi), Balaji, A.L. (Arjun Lakshmana), Lam, H. (Hilton), Lan, Q. (Qing), Lansingh, V.C. (Van C), Larson, H.J. (Heidi J), Larsson, A. (Anders), Lee, J.-T. (Jong-Tae), Leigh, P.N. (Nigel), Leinsalu, M. (Mall), Leung, R. (Ricky), Li, Y. (Yichong), Li, Y. (Yongmei), Lima, G.M.F. (Graça Maria Ferreira) de, Lin, H.-H. (Hsien-Ho), Lipshultz, S.E. (Steven), Liu, S. (Simin), Liu, Y. (Yang), Lloyd, B.K. (Belinda K), Lotufo, P.A. (Paulo A), Machado, V.M.P. (Vasco Manuel Pedro), Maclachlan, J.H. (Jennifer H), Magis-Rodriguez, C. (Carlos), Majdan, M. (Marek), Mapoma, C.C. (Christopher Chabila), Marcenes, W. (Wagner), Marzan, M.B. (Melvin Barrientos), Masci, J.R. (Joseph R), Mashal, R., Mason-Jones, A.J. (Amanda J), Mayosi, B.M. (Bongani), Mazorodze, T.T. (Tasara T), Mckay, M.J. (Michael), Meaney, M.J., Mehndiratta, M.M. (Man Mohan), Mejia-Rodriguez, F. (Fabiola), Melaku, Y.A. (Yohannes Adama), Memish, Z.A. (Ziad), Mendoza, W. (Walter), Miller, T.R. (Ted R), Mills, E.J. (Edward J), Mohammad, K.A. (Karzan Abdulmuhsin), Mokdad, A.H. (Ali H), Mola, G.L. (Glen Liddell), Monasta, L. (Lorenzo), Montico, M. (Marcella), Moore, A.R. (Ami R), Mori, R. (Riccardo), Moturi, W.N. (Wilkister Nyaora), Mukaigawara, M. (Mitsuru), Murthy, A.C. (Adeline C.), Naheed, A. (Aliya), Naidoo, K.S. (Kovin S), Naldi, L. (Lucia), Nangia, M. (Monika), Narayan, K.M.V. (Venkat), Nash, J.H.E. (John), Nejjari, C. (Chakib), Nelson, R.D. (Robert), Neupane, S.P. (Sudan Prasad), Newton, C. (Cameron), Ng, M. (Marie), Nisar, M.I. (Muhammad Imran), Nolte, S. (Sandra), Norheim, O.F. (Ole F), Nowaseb, V. (Vincent), Nyakarahuka, L. (Luke), Oh, I.-H. (In-Hwan), Ohkubo, T. (Takayoshi), Olusanya, B.O. (Bolajoko O), Omer, S.B. (Saad B), Opio, J.N. (John Nelson), Orisakwe, O.E. (Orish Ebere), Pandian, N.G. (Natesa), Papachristou, C., Caicedo, M.S. (Marco), Patten, J., Paul, V.K. (Vinod K), Pavlin, B.I. (Boris Igor), Pearce, N. (Neil), Pereira, D.M. (David M), Pervaiz, Z. (Zahid), Pesudovs, K. (Konrad), Petzold, M. (Max), Pourmalek, F. (Farshad), Qato, D. (Dima), Quezada, A.D. (Amado D), Quistberg, D.A. (D Alex), Rafay, A. (Anwar), Rahimi, K. (Kazem), Rahimi-Movaghar, V. (Vafa), Rahman, S.U. (Sajjad Ur), Raju, M. (Murugesan), Rana, S.M. (Saleem M), Razavi, H. (Homie), Reilly, R.Q. (Robert Quentin), Remuzzi, G. (Giuseppe), Richardus, J.H. (Jan Hendrik), Ronfani, L. (Luca), Roy, N. (Nadine) van, Sabin, M.L. (Miriam Lewis), Saeedi, M.Y. (Mohammad Yahya), Sahraian, M.A. (Mohammad Ali), Samonte, G.M.J. (Genesis May J), Sawhney, M.S. (Monika), Schneider, I.J.C. (Ione J C), Schwebel, D.C. (David C), Seedat, S. (Soraya), Sepanlou, S.G. (Sadaf G), Servan-Mori, E.E. (Edson E), Sheikhbahaei, S. (Sara), Shibuya, K. (Kenji), Shin, H.H. (Hwashin Hyun), Shiue, I. (Ivy), Shivakoti, R. (Rupak), Sigfusdottir, I.D. (Inga Dora), Silberberg, D.H. (Donald H), Silva, A.P. (Andrea P), Simard, J. (Jacques), Singh, J.A. (Jasvinder), Skirbekk, V. (Vegard), Sliwa, K. (Karen), Soneji, S. (Samir), Soshnikov, S.S. (Sergey S), Sreeramareddy, C.T. (Chandrashekhar T), Stathopoulou, V.K. (Vasiliki Kalliopi), Stroumpoulis, K. (Konstantinos), Swaminathan, S., Sykes, B.C. (Bryan), Tabb, K.M. (Karen M), Talongwa, R.T. (Roberto Tchio), Tenkorang, E.Y. (Eric Yeboah), Terkawi, A.S. (Abdullah Sulieman), Thomson, A.J. (Alan J), Thorne-Lyman, A.L. (Andrew L), Towbin, J.A. (Jeffrey A), Traebert, J. (Jefferson), Tran, B.X. (Bach X), Dimbuene, Z.T. (Zacharie Tsala), Tsilimbaris, M. (Miltiadis), Uchendu, U.S. (Uche S), Ukwaja, K.N. (Kingsley N), Vallely, S.R. (Stephen), Vasankari, T.J. (Tommi J), Venketasubramanian, N. (Narayanaswamy), Violante, F.S. (Francesco S), Vlassov, V.V. (Vasiliy Victorovich), Waller, P. (Patrick), Wallin, M.T. (Mitchell T), Wang, L. (Linhong), Wang, S.X., Wang, Y. (Yanping), Weichenthal, S. (Scott), Weiderpass, E. (Elisabete), Weintraub, R.G. (Robert G), Westerman, R. (Ronny), White, R.G. (Richard), Wilkinson, J.D. (James D), Williams, T.N. (Thomas Neil), Woldeyohannes, S.M. (Solomon Meseret), Wong, J.B. (John), Xu, G. (Gelin), Yang, Y.C. (Yang C), Yano, K.-I., Yip, P. (Paul), Yonemoto, N. (Naohiro), Yoon, S.-J. (Seok-Jun), Younis, M. (Mustafa), Yu, C. (Chuanhua), Jin, K.Y. (Kim Yun), El Sayed Zaki, M. (Maysaa), Zhao, Y. (Yong), Zheng, Y. (Yuhui), Balakrishnan, K. (Kalpana), Zhou, M. (Ming), Zhu, J. (Jun), Zou, X.N. (Xiao Nong), Lopez, A.D. (Alan D), Vos, T. (Theo), Murray, C.J.L. (Christopher), Ortblad, K.F. (Katrina F), Guinovart, C. (Caterina), Lim, S.S. (Stephen), Wolock, T.M. (Timothy M), Roberts, D.A. (D Allen), Dansereau, E.A. (Emily A), Graetz, N. (Nicholas), Barber, R.M. (Ryan), Brown, J.C. (Jonathan C), Wang, H. (Haidong), Duber, H.C. (Herbert C), Naghavi, M. (Morteza), Dicker, D. (Daniel), Dandona, L. (Lalit), Salomon, J.A. (Joshua), Heuton, K.R. (Kyle R), Foreman, K. (Kyle), Phillips, D.E. (David E), Fleming, T.D. (Thomas D), Flaxman, A.D. (Abraham D), Phillips, B.K. (Bryan K), Johnson, E.M. (Elizabeth), Coggeshall, M.S. (Megan S), Abd-Allah, F. (Foad), Abera, S.F. (Semaw Ferede), Abraham, J.P. (Jerry), Abubakar, I. (Ibrahim), Abu-Raddad, L.J. (Laith J), Abu-Rmeileh, N.M. (Niveen Me), Achoki, T. (Tom), Adeyemo, A. (Adebowale), Adou, A.K. (Arsène Kouablan), Adsuar, J.C. (José C), Agardh, E.E. (Emilie Elisabet), Akena, D. (Dickens), Al Kahbouri, M.J. (Mazin J), Alasfoor, D. (Deena), Albittar, M.I. (Mohammed I), Alcalá-Cerra, G. (Gabriel), Alegretti, M.A. (Miguel Angel), Alemu, G. (Getnet), Alfonso-Cristancho, R. (Rafael), Alhabib, S. (Samia), Ali, R. (Raghib), Alla, F. (Francois), Allen, P.J. (Peter), Alsharif, U. (Ubai), Alvarez, E. (Elena), Alvis-Guzman, N. (Nelson), Amankwaa, A.A. (Adansi A), Amare, A.T. (Azmeraw T), Amini, H. (Hassan), Ammar, K.A., Anderson, B.O. (Benjamin), Antonio, C.A.T. (Carl Abelardo T), Anwari, P. (Palwasha), Ärnlöv, J. (Johan), Arsenijevic, V.S.A. (Valentina S Arsic), Artaman, A. (Ali), Asghar, R.J. (Rana J), Assadi, R. (Reza), Atkins, L.S. (Lydia S), Badawi, A.F. (Alaa), Banerjee, A. (Amitava), Basu, S. (Saonli), Beardsley, J. (Justin), Bekele, T. (Tolesa), Bell, M.L. (Michelle Lee), Bernabe, E. (Eduardo), Beyene, T.J. (Tariku Jibat), Bhala, N. (Neeraj), Bhalla, P.L. (Pankaj), Bhutta, Z.A. (Zulfiqar A), Abdulhak, A.B. (Aref Bin), Binagwaho, A. (Agnes), Blore, J.D. (Jed D), Bose, D. (Dipan), Brainin, M. (Michael), Breitborde, N. (Nicholas), Castañeda-Orjuela, C.A. (Carlos A), Catalá-López, F. (Ferrán), Chadha, D., Chang, J.-C. (Jung-Chen), Chiang, Y.T., Chuang, T.-W. (Ting-Wu), Colomar, M. (Mercedes), Cooper Jr., L.T. (Leslie Trumbull), Cooper, C. (Charles), Courville, K.J. (Karen J), Cowie, M.R. (Martin R.), Criqui, M. (Michael), Dandona, R. (Rakhi), Dayama, A. (Anand), Leo, D. (Diego) de, Degenhardt, F., Del Pozo-Cruz, B. (Borja), Deribe, K. (Kebede), Des Jarlais, D.C. (Don C), Dessalegn, M. (Muluken), Dharmaratne, S.D. (Samath D), Dilmen, U. (Uǧur), Ding, E.L. (Eric), Driscoll, J.M., Durrani, Z., Ellenbogen, R.G. (Richard G), Ermakov, S. (Sergey), Esteghamati, A. (Alireza), Faraon, E.J.A. (Emerito Jose A), Farzadfar, F. (Farshad), Fereshtehnejad, S.-M. (Seyed-Mohammad), Fijabi, D.O. (Daniel Obadare), Forouzanfar, M.H. (Mohammad H), Fra.Paleo, U. (Urbano), Gaffikin, L. (Lynne), Gamkrelidze, A. (Amiran), Gankpé, F.G. (Fortuné Gbètoho), Geleijnse, J.M. (Marianne), Gessner, B.D. (Bradford D), Gibney, K.B. (Katherine B), Ginawi, I.A.M. (Ibrahim Abdelmageem Mohamed), Glaser, E.L. (Elizabeth L), Gona, P. (Philimon), Goto, A. (Akimoto), Gouda, H.N. (Hebe N), Gugnani, H.C. (Harish Chander), Gupta, R. (Rajeev), Hafezi-Nejad, N. (Nima), Hamadeh, R.R. (Randah Ribhi), Hammami, M. (Mouhanad), Hankey, G.J. (Graeme), Harb, H.L. (Hilda L), Haro, J.M. (Josep Maria), Havmoeller, R. (Rasmus), Hay, S.I. (Simon I), Hedayati, M.T. (Mohammad T), Pi, I.B.H. (Ileana B Heredia), Hoek, H.W. (Hans), Hornberger, J.C. (John C), Hosgood, H.D. (H Dean), Hotez, P.J. (Peter), Hoy, D.G. (Damian G), Huang, J. (Jian), Iburg, K.M. (Kim M), Idrisov, B.T. (Bulat T), Innos, K. (Kaire), Jacobsen, K.H. (Kathryn H), Jeemon, P. (Panniyammakal), Jensen, P.N. (Paul N), Jha, V. (Vivekanand), Jiang, G. (Guohong), Jonas, J.B., Juel, K. (Knud), Kan, H. (Haidong), Kankindi, I. (Ida), Karam, V. (Vincent), Karch, F. (Francois), Karema, C.K. (Corine Kakizi), Kaul, A. (Anil), Kawakami, N. (Norito), Kazi, D.S. (Dhruv S), Kemp, A.H. (Andrew H), Kengne, A.P. (Andre Pascal), Keren, A. (Andre), Kereselidze, M. (Maia), Khader, Y.S. (Yousef Saleh), Khalifa, S.E.A.H. (Shams Eldin Ali Hassan), Khan, E.A. (Ejaz Ahmed), Khang, Y.-H. (Young-Ho), Khonelidze, I. (Irma), Kinfu, Y. (Yohannes), Kinge, J.M. (Jonas M), Knibbs, L. (Luke), Kokubo, Y. (Yoshihiro), Kosen, S. (Soewarta), Defo, B.K. (Barthelemy Kuate), Kulkarni, V.S. (Veena S), Kulkarni, C. (Chanda), Kumar, K. (Kuldeep), Kumar, R.B. (Ravi B), Kumar, G.A. (G Anil), Kwan, G.F. (Gene F), Lai, T. (Taavi), Balaji, A.L. (Arjun Lakshmana), Lam, H. (Hilton), Lan, Q. (Qing), Lansingh, V.C. (Van C), Larson, H.J. (Heidi J), Larsson, A. (Anders), Lee, J.-T. (Jong-Tae), Leigh, P.N. (Nigel), Leinsalu, M. (Mall), Leung, R. (Ricky), Li, Y. (Yichong), Li, Y. (Yongmei), Lima, G.M.F. (Graça Maria Ferreira) de, Lin, H.-H. (Hsien-Ho), Lipshultz, S.E. (Steven), Liu, S. (Simin), Liu, Y. (Yang), Lloyd, B.K. (Belinda K), Lotufo, P.A. (Paulo A), Machado, V.M.P. (Vasco Manuel Pedro), Maclachlan, J.H. (Jennifer H), Magis-Rodriguez, C. (Carlos), Majdan, M. (Marek), Mapoma, C.C. (Christopher Chabila), Marcenes, W. (Wagner), Marzan, M.B. (Melvin Barrientos), Masci, J.R. (Joseph R), Mashal, R., Mason-Jones, A.J. (Amanda J), Mayosi, B.M. (Bongani), Mazorodze, T.T. (Tasara T), Mckay, M.J. (Michael), Meaney, M.J., Mehndiratta, M.M. (Man Mohan), Mejia-Rodriguez, F. (Fabiola), Melaku, Y.A. (Yohannes Adama), Memish, Z.A. (Ziad), Mendoza, W. (Walter), Miller, T.R. (Ted R), Mills, E.J. (Edward J), Mohammad, K.A. (Karzan Abdulmuhsin), Mokdad, A.H. (Ali H), Mola, G.L. (Glen Liddell), Monasta, L. (Lorenzo), Montico, M. (Marcella), Moore, A.R. (Ami R), Mori, R. (Riccardo), Moturi, W.N. (Wilkister Nyaora), Mukaigawara, M. (Mitsuru), Murthy, A.C. (Adeline C.), Naheed, A. (Aliya), Naidoo, K.S. (Kovin S), Naldi, L. (Lucia), Nangia, M. (Monika), Narayan, K.M.V. (Venkat), Nash, J.H.E. (John), Nejjari, C. (Chakib), Nelson, R.D. (Robert), Neupane, S.P. (Sudan Prasad), Newton, C. (Cameron), Ng, M. (Marie), Nisar, M.I. (Muhammad Imran), Nolte, S. (Sandra), Norheim, O.F. (Ole F), Nowaseb, V. (Vincent), Nyakarahuka, L. (Luke), Oh, I.-H. (In-Hwan), Ohkubo, T. (Takayoshi), Olusanya, B.O. (Bolajoko O), Omer, S.B. (Saad B), Opio, J.N. (John Nelson), Orisakwe, O.E. (Orish Ebere), Pandian, N.G. (Natesa), Papachristou, C., Caicedo, M.S. (Marco), Patten, J., Paul, V.K. (Vinod K), Pavlin, B.I. (Boris Igor), Pearce, N. (Neil), Pereira, D.M. (David M), Pervaiz, Z. (Zahid), Pesudovs, K. (Konrad), Petzold, M. (Max), Pourmalek, F. (Farshad), Qato, D. (Dima), Quezada, A.D. (Amado D), Quistberg, D.A. (D Alex), Rafay, A. (Anwar), Rahimi, K. (Kazem), Rahimi-Movaghar, V. (Vafa), Rahman, S.U. (Sajjad Ur), Raju, M. (Murugesan), Rana, S.M. (Saleem M), Razavi, H. (Homie), Reilly, R.Q. (Robert Quentin), Remuzzi, G. (Giuseppe), Richardus, J.H. (Jan Hendrik), Ronfani, L. (Luca), Roy, N. (Nadine) van, Sabin, M.L. (Miriam Lewis), Saeedi, M.Y. (Mohammad Yahya), Sahraian, M.A. (Mohammad Ali), Samonte, G.M.J. (Genesis May J), Sawhney, M.S. (Monika), Schneider, I.J.C. (Ione J C), Schwebel, D.C. (David C), Seedat, S. (Soraya), Sepanlou, S.G. (Sadaf G), Servan-Mori, E.E. (Edson E), Sheikhbahaei, S. (Sara), Shibuya, K. (Kenji), Shin, H.H. (Hwashin Hyun), Shiue, I. (Ivy), Shivakoti, R. (Rupak), Sigfusdottir, I.D. (Inga Dora), Silberberg, D.H. (Donald H), Silva, A.P. (Andrea P), Simard, J. (Jacques), Singh, J.A. (Jasvinder), Skirbekk, V. (Vegard), Sliwa, K. (Karen), Soneji, S. (Samir), Soshnikov, S.S. (Sergey S), Sreeramareddy, C.T. (Chandrashekhar T), Stathopoulou, V.K. (Vasiliki Kalliopi), Stroumpoulis, K. (Konstantinos), Swaminathan, S., Sykes, B.C. (Bryan), Tabb, K.M. (Karen M), Talongwa, R.T. (Roberto Tchio), Tenkorang, E.Y. (Eric Yeboah), Terkawi, A.S. (Abdullah Sulieman), Thomson, A.J. (Alan J), Thorne-Lyman, A.L. (Andrew L), Towbin, J.A. (Jeffrey A), Traebert, J. (Jefferson), Tran, B.X. (Bach X), Dimbuene, Z.T. (Zacharie Tsala), Tsilimbaris, M. (Miltiadis), Uchendu, U.S. (Uche S), Ukwaja, K.N. (Kingsley N), Vallely, S.R. (Stephen), Vasankari, T.J. (Tommi J), Venketasubramanian, N. (Narayanaswamy), Violante, F.S. (Francesco S), Vlassov, V.V. (Vasiliy Victorovich), Waller, P. (Patrick), Wallin, M.T. (Mitchell T), Wang, L. (Linhong), Wang, S.X., Wang, Y. (Yanping), Weichenthal, S. (Scott), Weiderpass, E. (Elisabete), Weintraub, R.G. (Robert G), Westerman, R. (Ronny), White, R.G. (Richard), Wilkinson, J.D. (James D), Williams, T.N. (Thomas Neil), Woldeyohannes, S.M. (Solomon Meseret), Wong, J.B. (John), Xu, G. (Gelin), Yang, Y.C. (Yang C), Yano, K.-I., Yip, P. (Paul), Yonemoto, N. (Naohiro), Yoon, S.-J. (Seok-Jun), Younis, M. (Mustafa), Yu, C. (Chuanhua), Jin, K.Y. (Kim Yun), El Sayed Zaki, M. (Maysaa), Zhao, Y. (Yong), Zheng, Y. (Yuhui), Balakrishnan, K. (Kalpana), Zhou, M. (Ming), Zhu, J. (Jun), Zou, X.N. (Xiao Nong), Lopez, A.D. (Alan D), and Vos, T. (Theo)
- Abstract
__Abstract__ Background: The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013, and an opportunity to assess whether accelerated progress has occured since the Millennium Declaration. Methods: To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately modified based on a systematic review of available studies of mortality with and without antiretroviral therapy (ART). For concentrated epidemics, we calibrated Spectrum models to fit vital registration data corrected for misclassification of HIV deaths. In generalised epidemics, we minimised a loss function to select epidemic curves most consistent with prevalence data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for corrected case-notifications, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-specific mortality using Bayesian meta-regression to generate consistent trends in all parameters. We analysed malaria mortality and incidence using an updated cause of death database, a systematic analysis of verbal autopsy validation studies for malaria, and recent studies (2010-13) of incidence, drug resistance, and coverage of insecticide-treated bednets. Findings: Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty interval 1·7 million to 2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3 million HIV deaths (1·3 to 1·5). At the peak of the epidemic in 2005, HIV caused 1·7 mil
- Published
- 2014
- Full Text
- View/download PDF
14. Plasma Advanced Oxidative Protein Products are Associated with Anti-oxidative Stress Pathway Genes and Malaria in a Longitudinal Cohort.
- Author
-
Zhang, Guicheng, Skorokhod, O., Khoo, S., Aguilar, R., Wiertsema, S., Nhabomba, A., Marrocco, T., McNamara-Smith, M., Manaca, M., Barbosa, A., Quintó, L., Hayden, C., Goldblatt, J., Guinovart, C., Alonso, P., Dobaño, C., Schwarzer, E., LeSouëf, P., Zhang, Guicheng, Skorokhod, O., Khoo, S., Aguilar, R., Wiertsema, S., Nhabomba, A., Marrocco, T., McNamara-Smith, M., Manaca, M., Barbosa, A., Quintó, L., Hayden, C., Goldblatt, J., Guinovart, C., Alonso, P., Dobaño, C., Schwarzer, E., and LeSouëf, P.
- Abstract
BACKGROUND: Advanced oxidation protein products (AOPP) are newly identified efficient oxidative stress biomarkers. In a longitudinal birth cohort the effects were investigated of genetic polymorphisms in five oxidative pathway genes on AOPP levels. METHODS: This study is part of a three-arm randomized, double-blind, placebo-controlled trial. Three hundred and twelve children were included in the present study with AOPP levels measured at 2.5, 5.5, 10.5, 15 and 24 months of age. Twelve polymorphisms were genotyped in five oxidative stress pathway genes: glutathione reductase (GSR), glutamylcysteine synthetase (GCLC), glutathione S-transferase (GST) P1, haem oxygenase 1 (HMOX1) and superoxide dismutase 2 (SOD2) in 298 children. There were 284 children assessed for anaemia and clinical malaria infection at the age of 24 months. RESULTS: Two principal components (PCA1 and PCA2) were derived from the AOPP levels measured at the five time points. PCA1 was significantly associated with anaemia (p = 0.0002), and PCA2 with clinical malaria infection (p = 0.047). In the K-Means Cluster Analysis based on levels of AOPP, children were clustered into two groups: Group A (lower AOPP levels) and Group B (higher AOPP levels). The cluster membership was significantly associated with anaemia (p =0.003) as well as with the GSR RS3594 polymorphism (p = 0.037). Mixed linear regression analyses found that the single nucleotide polymorphisms GCLC RS10948751 and HMOX1 RS17885925 were significantly associated with AOPP levels (p = 0.030 and p = 0.027, respectively).CONCLUSION: Plasma AOPP levels were predictive for anaemia and oxidative stress markers for clinical malaria infection in two year old children. Several polymorphisms in GCLC, GSR and HMOX1 genes were associated with oxidative stress status of these children
- Published
- 2014
15. The Role of Age and Exposure to Plasmodium falciparum in the Rate of Acquisition of Naturally Acquired Immunity: A Randomized Controlled Trial
- Author
-
Borrmann, S, Guinovart, C, Dobano, C, Bassat, Q, Nhabomba, A, Quinto, L, Manaca, MN, Aguilar, R, Rodriguez, MH, Barbosa, A, Aponte, JJ, Mayor, AG, Renom, M, Moraleda, C, Roberts, DJ, Schwarzer, E, Le Souef, PN, Schofield, L, Chitnis, CE, Doolan, DL, Alonso, PL, Borrmann, S, Guinovart, C, Dobano, C, Bassat, Q, Nhabomba, A, Quinto, L, Manaca, MN, Aguilar, R, Rodriguez, MH, Barbosa, A, Aponte, JJ, Mayor, AG, Renom, M, Moraleda, C, Roberts, DJ, Schwarzer, E, Le Souef, PN, Schofield, L, Chitnis, CE, Doolan, DL, and Alonso, PL
- Abstract
BACKGROUND: The rate of acquisition of naturally acquired immunity (NAI) against malaria predominantly depends on transmission intensity and age, although disentangling the effects of these is difficult. We used chemoprophylaxis to selectively control exposure to P. falciparum during different periods in infancy and explore the effect of age in the build-up of NAI, measured as risk of clinical malaria. METHODS AND FINDINGS: A three-arm double-blind randomized placebo-controlled trial was conducted in 349 infants born to Mozambican HIV-negative women. The late exposure group (LEG) received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months; the early exposure group (EEG) received placebo from 2.5-4.5 months and SP+AS from 5.5-9.5 months; and the control group (CG) received placebo from 2.5-9.5 months. Active and passive case detection (PCD) were conducted from birth to 10.5 and 24 months respectively. The primary endpoint was time to first or only episode of malaria in the second year detected by PCD. The incidence of malaria during the second year was of 0.50, 0.51 and 0.35 episodes/PYAR in the LEG, EEG and CG respectively (p = 0.379 for the adjusted comparison of the 3 groups). The hazard ratio of the adjusted comparison between the LEG and the CG was 1.38 (0.83-2.28, p = 0.642) and that between the EEG and the CG was 1.35 (0.81-2.24, p = 0.743). CONCLUSIONS: After considerably interfering with exposure during the first year of life, there was a trend towards a higher risk of malaria in the second year in children who had received chemoprophylaxis, but there was no significant rebound. No evidence was found that the age of first exposure to malaria affects the rate of acquisition of NAI. Thus, the timing of administration of antimalarial interventions like malaria vaccines during infancy does not appear to be a critical determinant. TRIAL REGISTRATION: ClinicalTrials.gov NCT00231452.
- Published
- 2012
16. Interleukin-10 (IL-10) polymorphisms are associated with IL-10: Production and clinical malaria in young children
- Author
-
Zhang, Guicheng, Manaca, M., McNamara-Smith, M., Mayor, A., Nhabomba, A., Berthoud, T., Khoo, S., Wiertsema, S., Aguilar, R., Barbosa, A., Quintó, L., Candelaria, P., Schultz, E., Hayden, C., Goldblatt, J., Guinovart, C., Alonso, P., LeSouëf, P., Dobaño, C., Zhang, Guicheng, Manaca, M., McNamara-Smith, M., Mayor, A., Nhabomba, A., Berthoud, T., Khoo, S., Wiertsema, S., Aguilar, R., Barbosa, A., Quintó, L., Candelaria, P., Schultz, E., Hayden, C., Goldblatt, J., Guinovart, C., Alonso, P., LeSouëf, P., and Dobaño, C.
- Abstract
The role of interleukin-10 (IL-10) in malaria remains poorly characterized. The aims of this study were to investigate (i) whether genetic variants of the IL-10 gene influence IL-10 production and (ii) whether IL-10 production as well as the genotypes and haplotypes of the IL-10 gene in young children and their mothers are associated with the incidence of clinical malaria in young children. We genotyped three IL-10 single nucleotide polymorphisms in 240 children and their mothers from a longitudinal prospective cohort and assessed the IL-10 production by maternal peripheral blood mononuclear cells (PBMCs) and cord blood mononuclear cells (CBMCs). Clinical episodes of Plasmodium falciparum malaria in the children were documented until the second year of life. The polymorphism IL-10 A-1082G (GCC haplotype of three SNPs in IL-10) in children was associated with IL-10 production levels by CBMC cultured with P. falciparum-infected erythrocytes (P=0.043), with the G allele linked to low IL-10 production capacity. The G allele in children was also significantly associated with a decreased risk for clinical malaria infection in their second year of life (P=0.016). Furthermore, IL-10 levels measured in maternal PBMCs cultured with infected erythrocytes were associated with increased risk of malaria infection in young children (P<0.001). In conclusion, IL-10 polymorphisms and IL-10 production capacity were associated with clinical malaria infections in young children. High IL-10 production capacity inherited from parents may diminish immunological protection against P. falciparum infection, thereby being a risk for increased malaria morbidity. © 2012, American Society for Microbiology.
- Published
- 2012
17. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1?4 in Mozambique
- Author
-
Macete, E., primary, Aponte, J. J., additional, Guinovart, C., additional, Sacarlal, J., additional, Ofori-Anyinam, O., additional, Mandomando, I., additional, Espasa, M., additional, Bevilacqua, C., additional, Leach, A., additional, Dubois, M. C., additional, Heppner, D. G., additional, Tello, L., additional, Milman, J., additional, Cohen, J., additional, Dubovsky, F., additional, Tornieporth, N., additional, Thompson, R., additional, and Alonso, P. L., additional
- Published
- 2006
- Full Text
- View/download PDF
18. Malaria: Burden of Disease
- Author
-
Guinovart, C., primary, Navia, M., additional, Tanner, M., additional, and Alonso, P., additional
- Published
- 2006
- Full Text
- View/download PDF
19. Consumo, hábitos alimentarios y estado nutricional de la población de Reus: IV. Distribución por edades y sexos del consumo de raizes y tubérculos, cereales, azúcares y frutas
- Author
-
Alimentació, Nutrició, Creixement i Salut Mental, Bioquímica i Biotecnologia, Universitat Rovira i Virgili, J Salas; I Font ; J Canals; L Guinovart; C Martí-Henneberg, Alimentació, Nutrició, Creixement i Salut Mental, Bioquímica i Biotecnologia, Universitat Rovira i Virgili, and J Salas; I Font ; J Canals; L Guinovart; C Martí-Henneberg
- Abstract
Una muestra escogida al azar del censo de Reus y analizada por medio recuerdo de 24 horas, evidencia consumo bajo en cereales, con una ingesta máxima entre los 11 y 15 años de edad (209,4± 19,0 g/hab/día) y alto en azúcar, con un máximo entre los 7 y 10 años (186,3 ± 31,8 g/hab/día). La ingesta de frutas tiende a aumentar con la edad. El consumo de raíces y tubérculos es similar al de otros países desarrollados. El bajo consumo de cereales es de valor ambivalente y el exceso de azúcares es hipercalórico, pudiendo producir caries y descompensar enfermedades., A random sample of Reus census was analyzed by the 24 hours recall method and shoued a low consumption of cereals with a maximal intake between 11 and 15 years of age (209,4± 19,0 g/person/day) and a high consumption of sugar with a maximal intake between 7 and 10 years of age (186,3 ± 31,8 g/person/day). The consumption of fruits increases with age. the consumption of roots and tubercles is similar than in other developed countries. The low consumption of sugars is hypercaloric, may cause dental caries and decompensate other diseases.
- Published
- 1985
20. Consumo, hábitos alimentarios y estado nutricional de la población de Reus: II. Distribución por edades y sexos del consumo de carne, huevos, pescado y legumbres
- Author
-
Alimentació, Nutrició, Creixement i Salut Mental, Bioquímica i Biotecnologia, Universitat Rovira i Virgili, J Salas; I Font; J Canals ; L Guinovart; C Martí-Henneberg, Alimentació, Nutrició, Creixement i Salut Mental, Bioquímica i Biotecnologia, Universitat Rovira i Virgili, and J Salas; I Font; J Canals ; L Guinovart; C Martí-Henneberg
- Abstract
We observed in a random sample of the Reus (Tarragona, Spain) census, analyzed by the method of "24 hours recall", a high intake of meat, fish, eggs and vegetables. An excess of meat in middle age males (231,8± 38,3 g/person/day) and too little among females (157,1 ± 21,3 g/person/day). A high consumption among children (112,6 ± 13,0 g/person/day) and low among the elderly (110,7 ± 34,4 g/person/day). A high consumption of eggs and fish at all ages. The consumption of vegetables is higher than in other developed countries. These dietary habits provide an excess of animal fat and in some groups not enough iron., En una muestra escogida al azar del censo de Reus, mediante el análisis por el método recuerdo de 24 horas, observamos una ingesta alta de carnes, pescados, huevos y legumbres. Se apreció un exceso de consumo de carne en las edades medias (231,8± 38,3 g/hab/día) en el sexo masculino y un defecto en el femenino (157,1 ± 21,3 g/hab/día), alto consumo en los niños (112,6 ± 13,0 g/hab/día) y bajo en los ancianos (110,7 ± 34,4 g/hab/día) y un alto consumo de huevos y pescado en todas las edades. la ingesta de legumbres es superior a la de otros países desarrollados. Esta tipología alimentaria es excesiva en lípidos animales y, en algún grupo, pobre en hierro.
- Published
- 1985
21. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
- Author
-
Cj, Murray, Kf, Ortblad, Guinovart C, Ss, Lim, Tm, Wolock, Da, Roberts, Ea, Dansereau, Graetz N, Rm, Barber, Jc, Brown, Wang H, Hc, Duber, Naghavi M, Dicker D, Dandona L, Ja, Salomon, Kr, Heuton, Foreman K, Phillips DE, and Td, Fleming
22. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
- Author
-
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, and Thompson R
- Published
- 2005
- Full Text
- View/download PDF
23. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
- Author
-
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitié MA, Dubovsky F, and Menéndez C
- Published
- 2004
- Full Text
- View/download PDF
24. High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.
- Author
-
de Jesus Á, Ernesto R, Massinga AJ, Nhacolo F, Munguambe K, Timana A, Nhacolo A, Messa A Jr, Massora S, Escola V, Enosse S, Gunjamo R, Funzamo C, Mwenda JM, Okeibunor J, Garcia-Basteiro A, Guinovart C, Mayor A, and Mandomando I
- Subjects
- Humans, Mozambique epidemiology, Seroepidemiologic Studies, Adult, Adolescent, Child, Preschool, Middle Aged, Young Adult, Child, Female, Male, Infant, Infant, Newborn, Aged, Immunoglobulin G blood, Immunoglobulin M blood, COVID-19 epidemiology, COVID-19 transmission, COVID-19 prevention & control, SARS-CoV-2 immunology, SARS-CoV-2 isolation & purification, SARS-CoV-2 genetics, Antibodies, Viral blood, Rural Population
- Abstract
Background: Mozambique was one of many African countries with limited testing capacity for SARS-CoV-2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age-specific seroprevalence of SARS-CoV-2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination., Methods: We conducted four community-based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS-CoV-2 antibodies. An age-stratified (0-19, 20-39, 40-59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS-CoV-2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT-qPCR., Results: SARS-CoV-2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals < 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys., Conclusions: A high seroprevalence to SARS-CoV-2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique., (© 2024 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
25. Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique.
- Author
-
Brokhattingen N, Matambisso G, da Silva C, Neubauer Vickers E, Pujol A, Mbeve H, Cisteró P, Maculuve S, Cuna B, Melembe C, Ndimande N, Palmer B, García-Ulloa M, Munguambe H, Montaña-Lopez J, Nhamussua L, Simone W, Chidimatembue A, Galatas B, Guinovart C, Rovira-Vallbona E, Saúte F, Aide P, Aranda-Díaz A, Greenhouse B, Macete E, and Mayor A
- Subjects
- Child, Animals, Female, Pregnancy, Humans, Prenatal Care methods, Mozambique epidemiology, Plasmodium falciparum genetics, Genomics, Malaria epidemiology, Malaria prevention & control, Parasites, Malaria, Falciparum epidemiology, Malaria, Falciparum prevention & control, Malaria, Falciparum parasitology
- Abstract
Routine sampling of pregnant women at first antenatal care (ANC) visits could make Plasmodium falciparum genomic surveillance more cost-efficient and convenient in sub-Saharan Africa. We compare the genetic structure of parasite populations sampled from 289 first ANC users and 93 children from the community in Mozambique between 2015 and 2019. Samples are amplicon sequenced targeting 165 microhaplotypes and 15 drug resistance genes. Metrics of genetic diversity and relatedness, as well as the prevalence of drug resistance markers, are consistent between the two populations. In an area targeted for elimination, intra-host genetic diversity declines in both populations (p = 0.002-0.007), while for the ANC population, population genetic diversity is also lower (p = 0.0004), and genetic relatedness between infections is higher (p = 0.002) than control areas, indicating a recent reduction in the parasite population size. These results highlight the added value of genomic surveillance at ANC clinics to inform about changes in transmission beyond epidemiological data., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
26. Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique.
- Author
-
Mayor A, Brokhattingen N, Matambisso G, da Silva C, Vickers EN, Pujol A, Mbeve H, Cistero P, Maculuve S, Cuna B, Melembe C, Ndimande N, Palmer B, García M, Munguambe H, Lopez JM, Nhamussa L, Simone W, Chidimatembue A, Galatas B, Guinovart C, Rovira-Vallbona E, Saute F, Aide P, Aranda-Díaz A, Greenhouse B, and Macete E
- Abstract
Routine sampling of pregnant women at first antenatal care (ANC) visits could make Plasmodium falciparum genomic surveillance more cost-efficient and convenient in sub-Saharan Africa. We compared the genetic structure of parasite populations sampled from 289 first ANC attendees and 93 children from the community in Mozambique between 2015 and 2019. Samples were amplicon sequenced targeting 165 microhaplotypes and 15 drug resistance genes. Metrics of genetic diversity and relatedness, as well as the prevalence of drug resistance markers, were consistent between the two populations. In an area targeted for elimination, intra-host genetic diversity declined in both populations (p=0.002-0.007), while for the ANC population, population genetic diversity was also lower (p=0.0004), and genetic relatedness between infections were higher (p=0.002) than control areas, indicating a recent reduction in the parasite population size. These results highlight the added value of genomic surveillance at ANC clinics to inform about changes in transmission beyond epidemiological data., Competing Interests: Declaration of interest All authors reported no conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
27. Detecting temporal and spatial malaria patterns from first antenatal care visits.
- Author
-
Pujol A, Brokhattingen N, Matambisso G, Mbeve H, Cisteró P, Escoda A, Maculuve S, Cuna B, Melembe C, Ndimande N, Munguambe H, Montaña J, Nhamússua L, Simone W, Tetteh KKA, Drakeley C, Gamain B, Chitnis CE, Chauhan V, Quintó L, Chidimatembue A, Martí-Soler H, Galatas B, Guinovart C, Saúte F, Aide P, Macete E, and Mayor A
- Subjects
- Child, Pregnancy, Female, Humans, Seroepidemiologic Studies, Health Facilities, Mozambique epidemiology, Prenatal Care, Malaria diagnosis, Malaria epidemiology
- Abstract
Pregnant women attending first antenatal care (ANC) visits represent a promising malaria surveillance target in Sub-Saharan Africa. We assessed the spatio-temporal relationship between malaria trends at ANC (n = 6471) and in children in the community (n = 3933) and at health facilities (n = 15,467) in southern Mozambique (2016-2019). ANC P. falciparum rates detected by quantitative polymerase chain reaction mirrored rates in children, regardless of gravidity and HIV status (Pearson correlation coefficient [PCC] > 0.8, χ²<1.1), with a 2-3 months lag. Only at rapid diagnostic test detection limits at moderate-to-high transmission, did multigravidae show lower rates than children (PCC = 0.61, 95%CI[-0.12-0.94]). Seroprevalence against the pregnancy-specific antigen VAR2CSA reflected declining malaria trends (PCC = 0.74, 95%CI[0.24-0.77]). 60% (9/15) of hotspots detected from health facility data (n = 6662) using a novel hotspot detector, EpiFRIenDs, were also identified with ANC data (n = 3616). Taken together, we show that ANC-based malaria surveillance offers contemporary information on temporal trends and geographic distribution of malaria burden in the community., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
28. Targeted and whole-genome sequencing reveal a north-south divide in P. falciparum drug resistance markers and genetic structure in Mozambique.
- Author
-
da Silva C, Boene S, Datta D, Rovira-Vallbona E, Aranda-Díaz A, Cisteró P, Hathaway N, Tessema S, Chidimatembue A, Matambisso G, Nhama A, Macete E, Pujol A, Nhamussua L, Galatas B, Guinovart C, Enosse S, De Carvalho E, Rogier E, Plucinski MM, Colborn J, Zulliger R, Saifodine A, Alonso PL, Candrinho B, Greenhouse B, Aide P, Saute F, and Mayor A
- Subjects
- Humans, Mozambique, Plasmodium falciparum genetics, Drug Resistance genetics, Whole Genome Sequencing, Genetic Structures, Antimalarials pharmacology, Antimalarials therapeutic use, Malaria, Falciparum drug therapy, Malaria, Falciparum epidemiology, Malaria, Falciparum parasitology, Malaria drug therapy
- Abstract
Mozambique is one of the four African countries which account for over half of all malaria deaths worldwide, yet little is known about the parasite genetic structure in that country. We performed P. falciparum amplicon and whole genome sequencing on 2251 malaria-infected blood samples collected in 2015 and 2018 in seven provinces of Mozambique to genotype antimalarial resistance markers and interrogate parasite population structure using genome-wide microhaplotyes. Here we show that the only resistance-associated markers observed at frequencies above 5% were pfmdr1-184F (59%), pfdhfr-51I/59 R/108 N (99%) and pfdhps-437G/540E (89%). The frequency of pfdhfr/pfdhps quintuple mutants associated with sulfadoxine-pyrimethamine resistance increased from 80% in 2015 to 89% in 2018 (p < 0.001), with a lower expected heterozygosity and higher relatedness of microhaplotypes surrounding pfdhps mutants than wild-type parasites suggestive of recent selection. pfdhfr/pfdhps quintuple mutants also increased from 72% in the north to 95% in the south (2018; p < 0.001). This resistance gradient was accompanied by a concentration of mutations at pfdhps-436 (17%) in the north, a south-to-north increase in the genetic complexity of P. falciparum infections (p = 0.001) and a microhaplotype signature of regional differentiation. The parasite population structure identified here offers insights to guide antimalarial interventions and epidemiological surveys., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
29. Genetic variants of TLR4, including the novel variant, rs5030719, and related genes are associated with susceptibility to clinical malaria in African children.
- Author
-
Ariff A, Song Y, Aguilar R, Nhabomba A, Manaca MN, Khoo SK, Wiertsema S, Bassat Q, Barbosa A, Quintó L, Laing IA, Guinovart C, Alonso PL, Dobaño C, Le Souëf P, and Zhang G
- Subjects
- Humans, Interleukin-13 genetics, Genetic Predisposition to Disease, Genotype, Polymorphism, Single Nucleotide, Toll-Like Receptor 4 genetics, Malaria epidemiology
- Abstract
Background: Malaria is a deadly disease caused by Plasmodium spp. Several blood phenotypes have been associated with malarial resistance, which suggests a genetic component to immune protection., Methods: One hundred and eighty-seven single nucleotide polymorphisms (SNPs) in 37 candidate genes were genotyped and investigated for associations with clinical malaria in a longitudinal cohort of 349 infants from Manhiça, Mozambique, in a randomized controlled clinical trial (RCT) (AgeMal, NCT00231452). Malaria candidate genes were selected according to involvement in known malarial haemoglobinopathies, immune, and pathogenesis pathways., Results: Statistically significant evidence was found for the association of TLR4 and related genes with the incidence of clinical malaria (p = 0.0005). These additional genes include ABO, CAT, CD14, CD36, CR1, G6PD, GCLM, HP, IFNG, IFNGR1, IL13, IL1A, IL1B, IL4R, IL4, IL6, IL13, MBL, MNSOD, and TLR2. Of specific interest, the previously identified TLR4 SNP rs4986790 and the novel finding of TRL4 SNP rs5030719 were associated with primary cases of clinical malaria., Conclusions: These findings highlight a potential central role of TLR4 in clinical malarial pathogenesis. This supports the current literature and suggests that further research into the role of TLR4, as well as associated genes, in clinical malaria may provide insight into treatment and drug development., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
30. Tracking SARS-CoV-2 introductions in Mozambique using pandemic-scale phylogenies: a retrospective observational study.
- Author
-
Martínez-Martínez FJ, Massinga AJ, De Jesus Á, Ernesto RM, Cano-Jiménez P, Chiner-Oms Á, Gómez-Navarro I, Guillot-Fernández M, Guinovart C, Sitoe A, Vubil D, Bila R, Gujamo R, Enosse S, Jiménez-Serrano S, Torres-Puente M, Comas I, Mandomando I, López MG, and Mayor A
- Subjects
- Humans, Pandemics prevention & control, Phylogeny, Mozambique epidemiology, Retrospective Studies, Prospective Studies, SARS-CoV-2 genetics, COVID-19 epidemiology, COVID-19 prevention & control
- Abstract
Background: From the start of the SARS-CoV-2 outbreak, global sequencing efforts have generated an unprecedented amount of genomic data. Nonetheless, unequal sampling between high-income and low-income countries hinders the implementation of genomic surveillance systems at the global and local level. Filling the knowledge gaps of genomic information and understanding pandemic dynamics in low-income countries is essential for public health decision making and to prepare for future pandemics. In this context, we aimed to discover the timing and origin of SARS-CoV-2 variant introductions in Mozambique, taking advantage of pandemic-scale phylogenies., Methods: We did a retrospective, observational study in southern Mozambique. Patients from Manhiça presenting with respiratory symptoms were recruited, and those enrolled in clinical trials were excluded. Data were included from three sources: (1) a prospective hospital-based surveillance study (MozCOVID), recruiting patients living in Manhiça, attending the Manhiça district hospital, and fulfilling the criteria of suspected COVID-19 case according to WHO; (2) symptomatic and asymptomatic individuals with SARS-CoV-2 infection recruited by the National Surveillance system; and (3) sequences from SARS-CoV-2-infected Mozambican cases deposited on the Global Initiative on Sharing Avian Influenza Data database. Positive samples amenable for sequencing were analysed. We used Ultrafast Sample placement on Existing tRees to understand the dynamics of beta and delta waves, using available genomic data. This tool can reconstruct a phylogeny with millions of sequences by efficient sample placement in a tree. We reconstructed a phylogeny (~7·6 million sequences) adding new and publicly available beta and delta sequences., Findings: A total of 5793 patients were recruited between Nov 1, 2020, and Aug 31, 2021. During this time, 133 328 COVID-19 cases were reported in Mozambique. 280 good quality new SARS-CoV-2 sequences were obtained after the inclusion criteria were applied and an additional 652 beta (B.1.351) and delta (B.1.617.2) public sequences were included from Mozambique. We evaluated 373 beta and 559 delta sequences. We identified 187 beta introductions (including 295 sequences), divided in 42 transmission groups and 145 unique introductions, mostly from South Africa, between August, 2020 and July, 2021. For delta, we identified 220 introductions (including 494 sequences), with 49 transmission groups and 171 unique introductions, mostly from the UK, India, and South Africa, between April and November, 2021., Interpretation: The timing and origin of introductions suggests that movement restrictions effectively avoided introductions from non-African countries, but not from surrounding countries. Our results raise questions about the imbalance between the consequences of restrictions and health benefits. This new understanding of pandemic dynamics in Mozambique can be used to inform public health interventions to control the spread of new variants., Funding: European and Developing Countries Clinical Trials, European Research Council, Bill & Melinda Gates Foundation, and Agència de Gestió d'Ajuts Universitaris i de Recerca., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Prospective surveillance study to detect antimalarial drug resistance, gene deletions of diagnostic relevance and genetic diversity of Plasmodium falciparum in Mozambique: protocol.
- Author
-
Mayor A, da Silva C, Rovira-Vallbona E, Roca-Feltrer A, Bonnington C, Wharton-Smith A, Greenhouse B, Bever C, Chidimatembue A, Guinovart C, Proctor JL, Rodrigues M, Canana N, Arnaldo P, Boene S, Aide P, Enosse S, Saute F, and Candrinho B
- Subjects
- Drug Resistance genetics, Female, Gene Deletion, Humans, Mozambique epidemiology, Multicenter Studies as Topic, Plasmodium falciparum genetics, Pregnancy, Prospective Studies, Antimalarials pharmacology, Antimalarials therapeutic use, Malaria epidemiology
- Abstract
Introduction: Genomic data constitute a valuable adjunct to routine surveillance that can guide programmatic decisions to reduce the burden of infectious diseases. However, genomic capacities remain low in Africa. This study aims to operationalise a functional malaria molecular surveillance system in Mozambique for guiding malaria control and elimination., Methods and Analyses: This prospective surveillance study seeks to generate Plasmodium falciparum genetic data to (1) monitor molecular markers of drug resistance and deletions in rapid diagnostic test targets; (2) characterise transmission sources in low transmission settings and (3) quantify transmission levels and the effectiveness of antimalarial interventions. The study will take place across 19 districts in nine provinces (Maputo city, Maputo, Gaza, Inhambane, Niassa, Manica, Nampula, Zambézia and Sofala) which span a range of transmission strata, geographies and malaria intervention types. Dried blood spot samples and rapid diagnostic tests will be collected across the study districts in 2022 and 2023 through a combination of dense (all malaria clinical cases) and targeted (a selection of malaria clinical cases) sampling. Pregnant women attending their first antenatal care visit will also be included to assess their value for molecular surveillance. We will use a multiplex amplicon-based next-generation sequencing approach targeting informative single nucleotide polymorphisms, gene deletions and microhaplotypes. Genetic data will be incorporated into epidemiological and transmission models to identify the most informative relationship between genetic features, sources of malaria transmission and programmatic effectiveness of new malaria interventions. Strategic genomic information will be ultimately integrated into the national malaria information and surveillance system to improve the use of the genetic information for programmatic decision-making., Ethics and Dissemination: The protocol was reviewed and approved by the institutional (CISM) and national ethics committees of Mozambique (Comité Nacional de Bioética para Saúde) and Spain (Hospital Clinic of Barcelona). Project results will be presented to all stakeholders and published in open-access journals., Trial Registration Number: NCT05306067., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
32. The epidemiology of severe malaria at Manhiça District Hospital, Mozambique: a retrospective analysis of 20 years of malaria admissions surveillance data.
- Author
-
Guinovart C, Sigaúque B, Bassat Q, Loscertales MP, Nhampossa T, Acácio S, Machevo S, Maculuve S, Bambo G, Mucavele H, Soriano-Gabarró M, Saifodine A, Nhacolo A, Nhalungo D, Sacoor C, Saúte F, Aponte JJ, Menéndez C, Macete E, and Alonso PL
- Subjects
- Adolescent, Child, Child, Preschool, Hospitals, District, Humans, Infant, Mozambique epidemiology, Retrospective Studies, Anemia, Malaria, Cerebral, Respiratory Distress Syndrome
- Abstract
Background: Most malaria burden estimates rely on modelling infection prevalence to case incidence data, with insufficient attention having been paid to the changing clinical presentation of severe disease and its relationship with changing transmission intensity. We present 20 years of longitudinal surveillance data to contribute to the understanding of the relationship between malaria transmission and the burden and clinical presentation of severe malaria and to inform policy., Methods: This retrospective analysis of clinical surveillance hospital data included all children younger than 15 years admitted with malaria to Manhiça District Hospital (MDH), Mozambique, from July 1, 1997, to June 30, 2017. Case fatality ratios (CFRs) were calculated as the number of patients who died having a specific diagnosis or syndrome divided by the total number of patients with known outcome admitted with that diagnosis or syndrome., Findings: Over the study period, 32 138 children were admitted to MDH with a malaria diagnosis. Malaria accounted for a large proportion of admissions, ranging from 4083 (76·9%) of 5307 admissions in 2000-01 to 706 (27·5%) of 2568 admissions in 2010-11. Since 2000-02, the absolute and relative number of malaria admissions and deaths presented a decreasing trend. The age pattern of patients with malaria shifted to older ages with a median age of 1·7 years (IQR 0·9-3·0) in 1997-2006 and 2·6 years (IQR 1·3-4·4) in 2006-17, although most malaria deaths (60-88% in 2009-17) still occurred in children younger than 5 years. The clinical presentation of severe malaria changed, with an increase in cerebral malaria and a decrease in severe anaemia and respiratory distress, leading to similar yearly cases for the three syndromes. CFRs for severe malaria fluctuated between 1·1% (2 of 186 in 2014-15) and 7·2% (11 of 152 in 2010-11), varying by severe malaria syndrome (3·3% [70 of 2105] for severe anaemia, 5·1% [191 of 3777] for respiratory distress, and 14·8% [72 of 487] for cerebral malaria). Overall malaria CFRs (1·8% [543 of 30 163]) did not vary by age group., Interpretation: Despite the unprecedented scale up of malaria control tools, malaria still represented around 30-40% of paediatric hospital admissions in 2006-17. The age shift towards older children was not accompanied by an increase in severe malaria or deaths; however, control programmes should consider adapting their high-risk target groups to include older children. Malaria remains a leading cause of disease and health-care system use and the massive unfinished malaria control agenda warrants intensified efforts., Funding: Spanish Agency for International Cooperation and Development., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Evaluating the Impact of Programmatic Mass Drug Administration for Malaria in Zambia Using Routine Incidence Data.
- Author
-
Fraser M, Miller JM, Silumbe K, Hainsworth M, Mudenda M, Hamainza B, Moonga H, Chizema Kawesha E, Mercer LD, Bennett A, Schneider K, Slater HC, Eisele TP, and Guinovart C
- Subjects
- Humans, Incidence, Mass Drug Administration, Zambia epidemiology, Antimalarials therapeutic use, Malaria drug therapy, Malaria epidemiology, Malaria prevention & control
- Abstract
Background: In 2016, the Zambian National Malaria Elimination Centre started programmatic mass drug administration (pMDA) campaigns with dihydroartemisinin-piperaquine as a malaria elimination tool in Southern Province. Two rounds were administered, 2 months apart (coverage 70% and 57%, respectively). We evaluated the impact of 1 year of pMDA on malaria incidence using routine data., Methods: We conducted an interrupted time series with comparison group analysis on monthly incidence data collected at the health facility catchment area (HFCA) level, with a negative binomial model using generalized estimating equations. Programmatic mass drug administration was conducted in HFCAs with greater than 50 cases/1000 people per year. Ten HFCAs with incidence rates marginally above this threshold (pMDA group) were compared with 20 HFCAs marginally below (comparison group)., Results: The pMDA HFCAs saw a 46% greater decrease in incidence at the time of intervention than the comparison areas (incidence rate ratio = 0.536; confidence interval = 0.337-0.852); however, incidence increased toward the end of the season. No HFCAs saw a transmission interruption., Conclusions: Programmatic mass drug administration, implemented during 1 year with imperfect coverage in low transmission areas with suboptimal vector control coverage, significantly reduced incidence. However, elimination will require additional tools. Routine data are important resources for programmatic impact evaluations and should be considered for future analyses., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.)
- Published
- 2022
- Full Text
- View/download PDF
34. SARS-CoV2 hospital surveillance and control system with contact tracing for patients and health care workers at a large reference hospital in Spain during the first wave: An observational descriptive study.
- Author
-
Llupià A, de la Torre-Pérez L, Granés L, Olivé V, Baron-Miras L, Torà I, Marin C, Grau J, Soriano I, Roel E, García-Diez M, López-Toribio M, Puig J, Guinovart C, Santana G, Fernández-Torres P, García-Basteiro AL, Prat A, Blanco-Rojas BJ, de Arquer M, Barroso S, Tortajada M, Varela P, Vilella A, and Trilla A
- Abstract
Background and Aims: During the first peak of the COVID-19 pandemic, the Preventive Medicine Department and the Occupational Health Department at Hospital Clinic de Barcelona (HCB), a large Spanish referral hospital, developed an innovative comprehensive SARS-CoV2 Surveillance and Control System (CoSy-19) in order to preserve patients' and health care workers' (HCWs) safety. We aim to describe the CoSy-19 and to assess the impact in the number of contacts that new cases generated along this time., Methods: Observational descriptive study of the findings of the activity of contact tracing of all cases received at the HCB during the first peak of COVID-19 in Spain (February 25th-May 3rd, 2020)., Results: A team of 204 professionals and volunteers performed 384 in-hospital contact-tracing studies which generated contacts, detecting 298 transmission chains which suggested preventive measures, generated around 22 000 follow-ups and more than 30 000 days of work leave. The number of contacts that new cases generated decreased during the study period., Conclusion: Coordination between Preventive Medicine and Occupational Health departments and agile information systems were necessary to preserve non-COVID activity and workers safety., Competing Interests: All the authors declare no conflict of interest., (© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
35. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial.
- Author
-
Grau-Pujol B, Camprubí-Ferrer D, Marti-Soler H, Fernández-Pardos M, Carreras-Abad C, Andrés MV, Ferrer E, Muelas-Fernandez M, Jullien S, Barilaro G, Ajanovic S, Vera I, Moreno L, Gonzalez-Redondo E, Cortes-Serra N, Roldán M, Arcos AA, Mur I, Domingo P, Garcia F, Guinovart C, and Muñoz J
- Subjects
- Adult, Double-Blind Method, Humans, Hydroxychloroquine adverse effects, SARS-CoV-2, Treatment Outcome, Pre-Exposure Prophylaxis, COVID-19 Drug Treatment
- Abstract
Background: Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period., Methods: We conducted a double-blind placebo-controlled randomized clinical trial in three hospitals in Barcelona, Spain. From 350 adult healthcare workers screened, we included 269 participants with no active or past SARS-CoV-2 infection (determined by a negative nasopharyngeal SARS-CoV-2 PCR and a negative serology against SARS-CoV-2). Participants allocated in the intervention arm (PrEP) received 400 mg of hydroxychloroquine daily for the first four consecutive days and subsequently, 400 mg weekly during the study period. Participants in the control group followed the same treatment schedule with placebo tablets., Results: 52.8% (142/269) of participants were in the hydroxychloroquine arm and 47.2% (127/269) in the placebo arm. Given the national epidemic incidence decay, only one participant in each group was diagnosed with COVID-19. The trial was stopped due to futility and our study design was deemed underpowered to evaluate any benefit regarding PrEP efficacy. Both groups showed a similar proportion of participants experiencing at least one adverse event (AE) (p=0.548). No serious AEs were reported. Almost all AEs (96.4%, 106/110) were mild. Only mild gastrointestinal symptoms were significantly higher in the hydroxychloroquine arm compared to the placebo arm (27.4% (39/142) vs 15.7% (20/127), p=0.041)., Conclusions: Although the efficacy of PrEP with hydroxychloroquine for preventing COVID-19 could not be evaluated, our study showed that PrEP with hydroxychloroquine at low doses is safe., Trial Registration: ClinicalTrials.gov NCT04331834 . Registered on April 2, 2020., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
36. SARS-CoV-2 transmission in students of public schools of Catalonia (Spain) after a month of reopening.
- Author
-
Llupià A, Borràs-Santos A, Guinovart C, Utzet M, Moriña D, and Puig J
- Subjects
- Adolescent, Child, Cohort Studies, Female, Humans, Incidence, Male, Public Sector, Retrospective Studies, SARS-CoV-2 pathogenicity, Spain epidemiology, Students, COVID-19 epidemiology, COVID-19 transmission, Schools trends
- Abstract
Introduction: SARS-CoV-2 transmission within schools and its contribution to community transmission are still a matter of debate., Methods: A retrospective cohort study in all public schools in Catalonia was conducted using publicly available data assessing the association between the number of reported SARS-CoV-2 cases among students and staff in weeks 1-2 (Sept 14-27th, 2020) of the academic year with school SARS-CoV-2 incidence among students in weeks 4-5. A multilevel Poisson regression model adjusted for the community incidence in the corresponding basic health area (BHA) and the type of school (primary or secondary), with random effects at the sanitary region and BHA levels, was performed., Results: A total of 2184 public schools opened on September 14th with 778,715 students. Multivariate analysis showed a significant association between the total number of SARS-CoV-2 cases in a centre in weeks 1-2 and the SARS-CoV-2 school incidence among students in weeks 4-5 (Risk Ratio (RR) 1.074, 95% CI 1.044-1.105, p-value <0.001). The adjusted BHA incidence in the first two weeks was associated with school incidence in weeks 4-5 (RR 1.002, 95% CI 1.002-1.003, p-value <0.001). Secondary schools showed an increased incidence in weeks 4 and 5 (RR primary vs secondary 1.709 95% CI 1.599-1.897, p-value <0.001)., Conclusions: Safety measures adopted by schools were not enough to stop related-to-school transmission in students and could be improved. The safest way to keep schools open is to reduce community transmission down to a minimum., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
37. Correction to: Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact.
- Author
-
Conner RO, Dieye Y, Hainsworth M, Tall A, Cissé B, Faye F, Sy MD, Ba A, Sene D, Ba S, Doucouré E, Thiam T, Diop M, Schneider K, Cissé M, Ba M, Scott CA, Kumar R, Asfaw E, Earle D, Guinot P, Steketee RW, and Guinovart C
- Abstract
An amendment to this paper has been published and can be accessed via the original article.
- Published
- 2020
- Full Text
- View/download PDF
38. A multiphase program for malaria elimination in southern Mozambique (the Magude project): A before-after study.
- Author
-
Galatas B, Saúte F, Martí-Soler H, Guinovart C, Nhamussua L, Simone W, Munguambe H, Hamido C, Montañà J, Muguande O, Maartens F, Luis F, Paaijmans K, Mayor A, Bassat Q, Menéndez C, Macete E, Rabinovich R, Alonso PL, Candrinho B, and Aide P
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Infection Control trends, Malaria, Falciparum epidemiology, Male, Middle Aged, Mosquito Control trends, Mozambique, Young Adult, Antimalarials administration & dosage, Infection Control methods, Malaria, Falciparum prevention & control, Malaria, Falciparum transmission, Mosquito Control methods
- Abstract
Background: Malaria eradication remains the long-term vision of the World Health Organization (WHO). However, whether malaria elimination is feasible in areas of stable transmission in sub-Saharan Africa with currently available tools remains a subject of debate. This study aimed to evaluate a multiphased malaria elimination project to interrupt Plasmodium falciparum malaria transmission in a rural district of southern Mozambique., Methods and Findings: A before-after study was conducted between 2015 and 2018 in the district of Magude, with 48,448 residents living in 10,965 households. Building on an enhanced surveillance system, two rounds of mass drug administrations (MDAs) per year over two years (phase I, August 2015-2017), followed by one year of reactive focal mass drug administrations (rfMDAs) (phase II, September 2017-June 2018) were deployed with annual indoor residual spraying (IRS), programmatically distributed long-lasting insecticidal nets (LLINs), and standard case management. The four MDA rounds covered 58%-72% of the population, and annual IRS reported coverage was >70%. Yearly parasite surveys and routine surveillance data were used to monitor the primary outcomes of the study-malaria prevalence and incidence-at baseline and annually since the onset of the project. Parasite prevalence by rapid diagnostic test (RDT) declined from 9.1% (95% confidence interval [CI] 7.0-11.8) in May 2015 to 2.6% (95% CI 2.0-3.4), representing a 71.3% (95% CI 71.1-71.4, p < 0.001) reduction after phase I, and to 1.4% (95% CI 0.9-2.2) after phase II. This represented an 84.7% (95% CI 81.4-87.4, p < 0.001) overall reduction in all-age prevalence. Case incidence fell from 195 to 75 cases per 1,000 during phase I (61.5% reduction) and to 67 per 1,000 during phase II (65.6% overall reduction). Interrupted time series (ITS) analysis was used to estimate the level and trend change in malaria cases associated with the set of project interventions and the number of cases averted. Phase I interventions were associated with a significant immediate reduction in cases of 69.1% (95% CI 57.5-77.6, p < 0.001). Phase II interventions were not associated with a level or trend change. An estimated 76.7% of expected cases were averted throughout the project (38,369 cases averted of 50,005 expected). One malaria-associated inpatient death was observed during the study period. There were 277 mild adverse events (AEs) recorded through the passive pharmacovigilance system during the four MDA rounds. One serious adverse event (SAE) that resulted in death was potentially related to the drug. The study was limited by the incomplete coverage of interventions, the quality of the routine and cross-sectional data collected, and the restricted accuracy of ITS analysis with a short pre-intervention period., Conclusion: In this study, we observed that the interventions deployed during the Magude project fell short of interrupting P. falciparum transmission with the coverages achieved. While new tools and strategies may be required to eventually achieve malaria elimination in stable transmission areas of sub-Saharan Africa, this project showed that innovative mixes of interventions can achieve large reductions in disease burden, a necessary step in the pathway towards elimination., Trial Registration: ClinicalTrials.gov NCT02914145., Competing Interests: The authors have declared that no competing interests exist. CM is a member of the Editorial Board of PLOS Medicine.
- Published
- 2020
- Full Text
- View/download PDF
39. Genetic evidence for imported malaria and local transmission in Richard Toll, Senegal.
- Author
-
Daniels RF, Schaffner SF, Dieye Y, Dieng G, Hainsworth M, Fall FB, Diouf CN, Ndiop M, Cisse M, Gueye AB, Sarr O, Guinot P, Deme AB, Bei AK, Sy M, Thwing J, MacInnis B, Earle D, Guinovart C, Sene D, Hartl DL, Ndiaye D, Steketee RW, Wirth DF, and Volkman SK
- Subjects
- Communicable Diseases, Imported classification, Communicable Diseases, Imported parasitology, Incidence, Malaria, Falciparum classification, Malaria, Falciparum parasitology, Plasmodium falciparum isolation & purification, Senegal epidemiology, Communicable Diseases, Imported epidemiology, Malaria, Falciparum epidemiology
- Abstract
Background: Malaria elimination efforts can be undermined by imported malaria infections. Imported infections are classified based on travel history., Methods: A genetic strategy was applied to better understand the contribution of imported infections and to test for local transmission in the very low prevalence region of Richard Toll, Senegal., Results: Genetic relatedness analysis, based upon molecular barcode genotyping data derived from diagnostic material, provided evidence for both imported infections and ongoing local transmission in Richard Toll. Evidence for imported malaria included finding that a large proportion of Richard Toll parasites were genetically related to parasites from Thiès, Senegal, a region of moderate transmission with extensive available genotyping data. Evidence for ongoing local transmission included finding parasites of identical genotype that persisted across multiple transmission seasons as well as enrichment of highly related infections within the households of non-travellers compared to travellers., Conclusions: These data indicate that, while a large number of infections may have been imported, there remains ongoing local malaria transmission in Richard Toll. These proof-of-concept findings underscore the value of genetic data to identify parasite relatedness and patterns of transmission to inform optimal intervention selection and placement.
- Published
- 2020
- Full Text
- View/download PDF
40. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
- Author
-
Grau-Pujol B, Camprubí D, Marti-Soler H, Fernández-Pardos M, Guinovart C, and Muñoz J
- Subjects
- Humans, Double-Blind Method, Pandemics prevention & control, Randomized Controlled Trials as Topic, SARS-CoV-2, Multicenter Studies as Topic, COVID-19 epidemiology, COVID-19 prevention & control, Health Personnel, Hydroxychloroquine adverse effects, Hydroxychloroquine therapeutic use, Pre-Exposure Prophylaxis, Occupational Exposure adverse effects, Infectious Disease Transmission, Patient-to-Professional prevention & control
- Abstract
Objectives: The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during an epidemic period. As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection., Trial Design: Multicentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial., Participants: Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la Santa Creu i Sant Pau of Barcelona, Hospital Plató of Barcelona, Hospital General de Granollers, Barcelona) will be recruited. Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and confirmed cases of COVID-19. For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate. Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any contraindication to hydroxychloroquine treatment., Intervention and Comparator: Eligible participants will be allocated to one of the two study groups: Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine® tablet) daily the first four consecutive days, followed by 400 mg weekly for a period of 6 months., Control Group: participants will receive placebo tablets with identical physical appearance to hydroxychloroquine 200 mg (Dolquine®) tablets following the same treatment schedule of the intervention group. Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines., Main Outcomes: The primary endpoint will be the number of confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative SARS-CoV-2 PCR and serology at day 0. As secondary endpoints, we will obtain: i) the SARS-CoV-2 seroconversion in the PrEP group compared to placebo during the 6 months of follow-up in healthcare workers with negative serology at day 0; ii) the occurrence of any adverse event related with hydroxychloroquine treatment; iii) the incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers in the non-PrEP group, among the total of healthcare workers included in the non-PrEP group during the study period; iv) the risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19; v) a repository of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection., Randomisation: Participants meeting all eligibility requirements will be allocated to one of the two study arms (PrEP with hydroxychloroquine or non-PrEP control group) in a 1:1 ratio using simple randomisation with computer generated random numbers., Blinding (masking): Participants, doctors and nurses caring for participants, and investigators assessing the outcomes will be blinded to group assignment., Numbers to Be Randomised (sample Size): Each intervention group will have 220 participants, giving a total of 440 participants., Trial Status: The current protocol version is 1.5, 2
nd of June 2020. Two hundred and seventy-fiveparticipants were recruited and completed first month follow-up until date. The estimated sample size could not be reached yet due to the declining national epidemic curve. Thus, 275 is the total number of participants included until date. The study has been suspended (26th of June) until new epidemic curve occurs., Trial Registration: This trial was registered on April 2nd 2020 at clinicaltrials.gov with the number NCT04331834., Full Protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.- Published
- 2020
- Full Text
- View/download PDF
41. Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact.
- Author
-
Conner RO, Dieye Y, Hainsworth M, Tall A, Cissé B, Faye F, Sy MD, Ba A, Sene D, Ba S, Doucouré E, Thiam T, Diop M, Schneider K, Cissé M, Ba M, Earle D, Guinot P, Steketee RW, and Guinovart C
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Feasibility Studies, Female, Fever diagnosis, Fever parasitology, Fever prevention & control, Humans, Infant, Malaria, Falciparum parasitology, Malaria, Falciparum prevention & control, Male, Middle Aged, Senegal, Young Adult, Antimalarials therapeutic use, Artemisinins therapeutic use, Diagnostic Tests, Routine statistics & numerical data, Malaria, Falciparum diagnosis, Mass Screening statistics & numerical data, Plasmodium falciparum isolation & purification, Quinolines therapeutic use
- Abstract
Background: Population-wide interventions using malaria testing and treatment might decrease the reservoir of Plasmodium falciparum infection and accelerate towards elimination. Questions remain about their effectiveness and evidence from different transmission settings is needed., Methods: A pilot quasi-experimental study to evaluate a package of population-wide test and treat interventions was conducted in six health facility catchment areas (HFCA) in the districts of Kanel, Linguère, and Ranérou (Senegal). Seven adjacent HFCAs were selected as comparison. Villages within the intervention HFCAs were stratified according to the 2013 incidences of passively detected malaria cases, and those with an incidence ≥ 15 cases/1000/year were targeted for a mass test and treat (MTAT) in September 2014. All households were visited, all consenting individuals were tested with a rapid diagnostic test (RDT), and, if positive, treated with dihydroartemisinin-piperaquine. This was followed by weekly screening, testing and treatment of fever cases (PECADOM++) until the end of the transmission season in January 2015. Villages with lower incidence received only PECADOM++ or case investigation. To evaluate the impact of the interventions over that transmission season, the incidence of passively detected, RDT-confirmed malaria cases was compared between the intervention and comparison groups with a difference-in-difference analysis using negative binomial regression with random effects on HFCA., Results: During MTAT, 89% (2225/2503) of households were visited and 86% (18,992/22,170) of individuals were tested, for a combined 77% effective coverage. Among those tested, 291 (1.5%) were RDT positive (range 0-10.8 by village), of whom 82% were < 20 years old and 70% were afebrile. During the PECADOM++ 40,002 visits were conducted to find 2784 individuals reporting fever, with an RDT positivity of 6.5% (170/2612). The combination of interventions resulted in an estimated 38% larger decrease in malaria case incidence in the intervention compared to the comparison group (adjusted incidence risk ratio = 0.62, 95% CI 0.45-0.84, p = 0.002). The cost of the MTAT was $14.3 per person., Conclusions: It was operationally feasible to conduct MTAT and PECADOM++ with high coverage, although PECADOM++ was not an efficient strategy to complement MTAT. The modest impact of the intervention package suggests a need for alternative or complementary strategies.
- Published
- 2020
- Full Text
- View/download PDF
42. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital.
- Author
-
Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, Santano R, Sanz S, Méndez S, Llupià A, Aguilar R, Alonso S, Barrios D, Carolis C, Cisteró P, Chóliz E, Cruz A, Fochs S, Jairoce C, Hecht J, Lamoglia M, Martínez MJ, Mitchell RA, Ortega N, Pey N, Puyol L, Ribes M, Rosell N, Sotomayor P, Torres S, Williams S, Barroso S, Vilella A, Muñoz J, Trilla A, Varela P, Mayor A, and Dobaño C
- Subjects
- Adult, Asymptomatic Infections epidemiology, Betacoronavirus genetics, Betacoronavirus isolation & purification, COVID-19, Coronavirus Infections blood, Coronavirus Infections diagnosis, Female, Humans, Male, Middle Aged, Occupational Health, Pandemics, Pneumonia, Viral blood, Pneumonia, Viral diagnosis, RNA, Viral blood, Risk Factors, SARS-CoV-2, Seroepidemiologic Studies, Spain epidemiology, Antibodies, Viral blood, Betacoronavirus immunology, Coronavirus Infections epidemiology, Health Personnel, Pneumonia, Viral epidemiology
- Abstract
Health care workers (HCW) are a high-risk population to acquire SARS-CoV-2 infection from patients or other fellow HCW. This study aims at estimating the seroprevalence against SARS-CoV-2 in a random sample of HCW from a large hospital in Spain. Of the 578 participants recruited from 28 March to 9 April 2020, 54 (9.3%, 95% CI: 7.1-12.0) were seropositive for IgM and/or IgG and/or IgA against SARS-CoV-2. The cumulative prevalence of SARS-CoV-2 infection (presence of antibodies or past or current positive rRT-PCR) was 11.2% (65/578, 95% CI: 8.8-14.1). Among those with evidence of past or current infection, 40.0% (26/65) had not been previously diagnosed with COVID-19. Here we report a relatively low seroprevalence of antibodies among HCW at the peak of the COVID-19 epidemic in Spain. A large proportion of HCW with past or present infection had not been previously diagnosed with COVID-19, which calls for active periodic rRT-PCR testing in hospital settings.
- Published
- 2020
- Full Text
- View/download PDF
43. Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control.
- Author
-
Cirera L, Galatas B, Alonso S, Paaijmans K, Mamuquele M, Martí-Soler H, Guinovart C, Munguambe H, Luis F, Nhantumbo H, Montañà J, Bassat Q, Candrinho B, Rabinovich R, Macete E, Aide P, Alonso P, Saúte F, and Sicuri E
- Subjects
- Humans, Mass Drug Administration statistics & numerical data, Mozambique, Cost-Benefit Analysis, Malaria economics, Malaria prevention & control, Mass Drug Administration economics
- Abstract
Background: As new combinations of interventions aiming at interrupting malaria transmission are under evaluation, understanding the associated economic costs and benefits is critical for decision-making. This study assessed the economic cost and cost-effectiveness of the Magude project, a malaria elimination initiative implemented in a district in southern Mozambique (i.e. Magude) between August 2015-June 2018. This project piloted a combination of two mass drug administration (MDA) rounds per year for two consecutive years, annual rounds of universal indoor residual spraying (IRS) and a strengthened surveillance and response system on the back of universal long-lasting insecticide treated net (LLIN) coverage and routine case management implemented by the National Malaria Control Program (NMCP). Although local transmission was not interrupted, the project achieved large reductions in the burden of malaria in the target district., Methods: We collected weekly economic data, estimated costs from the project implementer perspective and assessed the incremental cost-effectiveness ratio (ICER) associated with the Magude project as compared to routine malaria control activities, the counterfactual. We estimated disability-adjusted life years (DALYs) for malaria cases and deaths and assessed the variation of the ICER over time to capture the marginal costs and effectiveness associated with subsequent phases of project implementation. We used deterministic and probabilistic sensitivity analyses to account for uncertainty and built an alternative scenario by assuming the implementation of the interventions from a governmental perspective. Economic costs are provided in constant US$2015., Results: After three years, the Magude project averted a total of 3,171 DALYs at an incremental cost of $2.89 million and an average yearly cost of $20.7 per targeted person. At an average cost of $19.4 per person treated per MDA round, the social mobilization and distribution of door-to-door MDA contributed to 53% of overall resources employed, with personnel and logistics being the main cost drivers. The ICER improved over time as a result of decreasing costs and improved effectiveness. The overall ICER was $987 (CI95% 968-1,006) per DALY averted, which is below the standard cost-effectiveness (CE) threshold of $1,404/DALY averted, three times the gross domestic product (GDP) per capita of Mozambique, but above the threshold of interventions considered highly cost-effective (one time the GDP per capita or $468/DALY averted) and above the recently suggested thresholds based on the health opportunity cost ($537 purchasing power parity/ DALY averted). A significantly lower ICER was obtained in the implementation scenario from a governmental perspective ($441/DALY averted)., Conclusion: Despite the initial high costs and volume of resources associated with its implementation, MDA in combination with other existing malaria control interventions, can be a cost-effective strategy to drastically reduce transmission in areas of low to moderate transmission in sub-Saharan Africa. However, further studies are needed to understand the capacity of the health system and financial affordability to scale up such strategies at regional or national level., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
44. Demographic and health community-based surveys to inform a malaria elimination project in Magude district, southern Mozambique.
- Author
-
Galatas B, Nhacolo A, Marti H, Munguambe H, Jamise E, Guinovart C, Cirera L, Amone F, Macete E, Bassat Q, Rabinovich R, Alonso P, Aide P, Saute F, and Sacoor C
- Subjects
- Demography, Health Services Accessibility, Humans, Mozambique epidemiology, Poverty, Rural Population, Health Surveys, Malaria epidemiology, Malaria prevention & control, Mosquito Control methods, Public Health
- Abstract
Objectives: A Demographic and Health Platform was established in Magude in 2015, prior to the deployment of a project aiming to evaluate the feasibility of malaria elimination in southern Mozambique, named the Magude project. This platform aimed to inform the design, implementation and evaluation of the Magude project, through the identification of households and population; and the collection of demographic, health and malaria information., Setting: Magude is a rural district of southern Mozambique which borders South Africa. It has nine peripheral health facilities and one referral health centre with an inpatient ward., Intervention: A baseline census enumerated and geolocated all the households, and their resident and non-resident members, collecting demographic and socio-economic information, and data on the coverage and usage of malaria control tools. Inpatient and outpatient data during the 5 years (2010 to 2014) before the survey were obtained from the district health authorities. The demographic platform was updated in 2016., Results: The baseline census conducted in 2015 reported 48 448 (92.1%) residents and 4133 (7.9%) non-residents, and 10 965 households. Magude's population is predominantly young, half of the population has no formal education and the main economic activities are agriculture and fishing. Houses are mainly built with traditional non-durable materials and have poor sanitation facilities. Between 2010 and 2014, malaria was the most common cause of all-age inpatient discharges (representing 20% to 40% of all discharges), followed by HIV (12% to 22%) and anaemia (12% to 15%). In early 2015, all-age bed-net usage was between 21.8% and 27.1% and the reported coverage of indoor residual spraying varied across the district between 30.7% and 79%., Conclusion: This study revealed that Magude has limited socio-economic conditions, poor access to healthcare services and low coverage of malaria vector control interventions. Thus, Magude represented an area where it is most pressing to demonstrate the feasibility of malaria elimination., Trial Registration Number: NCT02914145; Pre-results., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
45. Monitoring the COVID-19 epidemic in the context of widespread local transmission.
- Author
-
García-Basteiro AL, Chaccour C, Guinovart C, Llupià A, Brew J, Trilla A, and Plasencia A
- Subjects
- Betacoronavirus isolation & purification, COVID-19, Coronavirus Infections diagnosis, Coronavirus Infections transmission, Cost of Illness, Epidemiological Monitoring, Humans, Italy epidemiology, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral transmission, SARS-CoV-2, Spain epidemiology, Coronavirus Infections epidemiology, Pneumonia, Viral epidemiology
- Published
- 2020
- Full Text
- View/download PDF
46. Changing plasma cytokine, chemokine and growth factor profiles upon differing malaria transmission intensities.
- Author
-
Aguilar R, Campo JJ, Chicuecue S, Cisteró P, Català A, Luis L, Ubillos I, Galatas B, Aide P, Guinovart C, Moncunill G, and Dobaño C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers blood, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Immunity, Cellular physiology, Infant, Infant, Newborn, Malaria, Falciparum parasitology, Male, Middle Aged, Mozambique epidemiology, Prevalence, Young Adult, Malaria, Falciparum epidemiology, Plasmodium falciparum isolation & purification
- Abstract
Background: Malaria epidemiological and immunological data suggest that parasite tolerance wanes in the absence of continuous exposure to the parasite, potentially enhancing pathogenesis. The expansion of control interventions and elimination campaigns raises the necessity to better understand the host factors leading to susceptibility or tolerance that are affected by rapid changes in malaria transmission intensity (MTI). Mediators of cellular immune responses are responsible for the symptoms and pathological alterations during disease and are expected to change rapidly upon malaria exposure or cessation., Methods: The plasma concentrations of 30 cytokine, chemokine and growth factors in individuals of all ages from a malaria endemic area of southern Mozambique were compared between 2 years of different MTI: 2010 (lower, n = 234) and 2013 (higher, n = 143). The effect of the year on the correlations between cytokines, chemokines and growth factors and IgGs to Plasmodium falciparum (markers of exposure) was explored. The effects of age, sex, neighbourhood and parasitaemia on analyte levels and their interactions with year were also assessed., Results: An inverse correlation of several cellular immune mediators with malarial antibodies in 2013, and a lack of correlation or even a positive correlation in 2010 were observed. Most cytokines, chemokines and growth factors, regardless of their immune function, had higher concentrations in 2010 compared with 2013 in P. falciparum-infected and uninfected subjects. Age and neighbourhood showed an effect on analyte concentrations., Conclusions: The results show a different regulation of the cellular immune response in 2010 vs 2013 which could be related to a loss of immune-tolerance after a decline in MTI in 2010 and previous years, and a rapid re-establishment of tolerance as a consequence of more continuous exposure as MTI began increasing in 2012. Cellular immune mediators warrant further investigation as possible surrogates of MTI-associated host susceptibility or tolerance.
- Published
- 2019
- Full Text
- View/download PDF
47. Differential expression of var subgroups and PfSir2a genes in afebrile Plasmodium falciparum malaria: a matched case-control study.
- Author
-
Gupta H, Galatas B, Matambisso G, Nhamussua L, Cisteró P, Bassat Q, Casellas A, Macete E, Aponte JJ, Sacoor C, Alonso P, Saúte F, Guinovart C, Aide P, and Mayor A
- Subjects
- Adolescent, Adult, Case-Control Studies, Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Infant, Infant, Newborn, Malaria, Falciparum parasitology, Male, Mozambique, Protozoan Proteins metabolism, Young Adult, Gene Expression, Malaria, Falciparum diagnosis, Plasmodium falciparum genetics, Protozoan Proteins genetics
- Abstract
Background: Poor knowledge on the afebrile Plasmodium falciparum biology limits elimination approaches to target asymptomatic malaria. Therefore, the association of parasite factors involved in cytoadhesion, parasite multiplication and gametocyte maturation with afebrile malaria was assessed., Methods: Plasmodium falciparum isolates were collected from febrile (axillary temperature ≥ 37.5 °C or a reported fever in the previous 24 h) and afebrile (fever neither at the visit nor in the previous 24 h) individuals residing in Southern Mozambique. var, PfSir2a and Pfs25 transcript levels were determined by reverse transcriptase quantitative PCRs (RT-qPCRs) and compared among 61 pairs of isolates matched by parasite density, age and year of sample collection., Results: The level of varC and PfSir2a transcripts was higher in P. falciparum isolates from afebrile individuals (P ≤ 0.006), while varB and DC8 genes (P ≤ 0.002) were higher in isolates from individuals with febrile infections. After adjusting the analysis by area of residence, doubling the relative transcript unit (RTU) of varC and PfSir2a was associated with a 29.7 (95% CI 4.6-192.3) and 8.5 (95% CI 1.9-32.2) fold increases, respectively, of the odds of being afebrile. In contrast, doubling the RTU of varB and DC8 was associated with a 0.8 (95% CI 0.05-0.6) and 0.2 (95% CI 0.04-0.6) fold changes, respectively, of the odds of being afebrile. No significant differences were found for Pfs25 transcript levels in P. falciparum isolates from afebrile and febrile individuals., Conclusions: var and gametocyte-specific transcript patterns in febrile and afebrile infections from southern Mozambique matched by age, parasite density and recruitment period suggest similar transmissibility but differential expression of variant antigens involved in cytoadhesion and immune-evasion.
- Published
- 2019
- Full Text
- View/download PDF
48. A Balanced Proinflammatory and Regulatory Cytokine Signature in Young African Children Is Associated With Lower Risk of Clinical Malaria.
- Author
-
Dobaño C, Nhabomba AJ, Manaca MN, Berthoud T, Aguilar R, Quintó L, Barbosa A, Rodríguez MH, Jiménez A, Groves PL, Santano R, Bassat Q, Aponte JJ, Guinovart C, Doolan DL, and Alonso PL
- Subjects
- Antimalarials therapeutic use, Artemisinins therapeutic use, Cell Extracts pharmacology, Chemoprevention, Child, Preschool, Cytokines immunology, Double-Blind Method, Erythrocytes chemistry, Humans, Infant, Infant, Newborn, Inflammation, Leukocytes, Mononuclear drug effects, Mozambique, Pyrimethamine therapeutic use, Risk Factors, Schizonts, Sulfadoxine therapeutic use, Transcriptome, Cytokines blood, Leukocytes, Mononuclear immunology, Malaria, Falciparum immunology, Malaria, Falciparum prevention & control
- Abstract
Background: The effect of timing of exposure to first Plasmodium falciparum infections during early childhood on the induction of innate and adaptive cytokine responses and their contribution to the development of clinical malaria immunity is not well established., Methods: As part of a double-blind, randomized, placebo-controlled trial in Mozambique using monthly chemoprophylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively control timing of malaria exposure during infancy, peripheral blood mononuclear cells collected from participants at age 2.5, 5.5, 10.5, 15, and 24 months were stimulated ex vivo with parasite schizont and erythrocyte lysates. Cytokine messenger RNA expressed in cell pellets and proteins secreted in supernatants were quantified by reverse-transcription quantitative polymerase chain reaction and multiplex flow cytometry, respectively. Children were followed up for clinical malaria from birth until 4 years of age., Results: Higher proinflammatory (interleukin [IL] 1, IL-6, tumor necrosis factor) and regulatory (IL-10) cytokine concentrations during the second year of life were associated with reduced incidence of clinical malaria up to 4 years of age, adjusting by chemoprophylaxis and prior malaria exposure. Significantly lower concentrations of antigen-specific T-helper 1 (IL-2, IL-12, interferon-γ) and T-helper 2 (IL-4, IL-5) cytokines by 2 years of age were measured in children undergoing chemoprophylaxis compared to children receiving placebo (P < .03)., Conclusions: Selective chemoprophylaxis altering early natural exposure to malaria blood stage antigens during infancy had a significant effect on T-helper lymphocyte cytokine production >1 year later. Importantly, a balanced proinflammatory and anti-inflammatory cytokine signature, probably by innate cells, around age 2 years was associated with protective clinical immunity during childhood., Clinical Trials Registration: NCT00231452., (© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
49. Setting the scene and generating evidence for malaria elimination in Southern Mozambique.
- Author
-
Aide P, Candrinho B, Galatas B, Munguambe K, Guinovart C, Luis F, Mayor A, Paaijmans K, Fernández-Montoya L, Cirera L, Bassat Q, Mocumbi S, Menéndez C, Nhalungo D, Nhacolo A, Rabinovich R, Macete E, Alonso P, and Saúte F
- Subjects
- Capital Financing, Communicable Disease Control economics, Communicable Disease Control methods, Disease Eradication economics, Disease Eradication methods, Health Policy, Humans, Mosquito Control economics, Mosquito Control methods, Mosquito Control organization & administration, Mozambique epidemiology, Communicable Disease Control organization & administration, Disease Eradication organization & administration, Disease Transmission, Infectious prevention & control, Malaria epidemiology, Malaria prevention & control
- Abstract
Mozambique has historically been one of the countries with the highest malaria burden in the world. Starting in the 1960s, malaria control efforts were intensified in the southern region of the country, especially in Maputo city and Maputo province, to aid regional initiatives aimed to eliminate malaria in South Africa and eSwatini. Despite significant reductions in malaria prevalence, elimination was never achieved. Following the World Health Organization's renewed vision of a malaria-free-world, and considering the achievements from the past, the Mozambican National Malaria Control Programme (NMCP) embarked on the development and implementation of a strategic plan to accelerate from malaria control to malaria elimination in southern Mozambique. An initial partnership, supported by the Bill and Melinda Gates Foundation and the La Caixa Foundation, led to the creation of the Mozambican Alliance Towards the Elimination of Malaria (MALTEM) and the Malaria Technical and Advisory Committee (MTAC) to promote national ownership and partner coordination to work towards the goal of malaria elimination in local and cross-border initiatives. Surveillance systems to generate epidemiological and entomological intelligence to inform the malaria control strategies were strengthened, and an impact and feasibility assessment of various interventions aimed to interrupt malaria transmission were conducted in Magude district (Maputo Province) through the "Magude Project". The primary aim of this project was to generate evidence to inform malaria elimination strategies for southern Mozambique. The goal of malaria elimination in areas of low transmission intensity is now included in the national malaria strategic plan for 2017-22 and the NMCP and its partners have started to work towards this goal while evidence continues to be generated to move the national elimination agenda forward.
- Published
- 2019
- Full Text
- View/download PDF
50. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination.
- Author
-
Greenhouse B, Daily J, Guinovart C, Goncalves B, Beeson J, Bell D, Chang MA, Cohen JM, Ding X, Domingo G, Eisele TP, Lammie PJ, Mayor A, Merienne N, Monteiro W, Painter J, Rodriguez I, White M, Drakeley C, and Mueller I
- Abstract
Measurement of malaria specific antibody responses represents a practical and informative method for malaria control programs to assess recent exposure to infection. Technical advances in recombinant antigen production, serological screening platforms, and analytical methods have enabled the identification of several target antigens for laboratory based and point-of-contact tests. Questions remain as to how these serological assays can best be integrated into malaria surveillance activities to inform programmatic decision-making. This report synthesizes discussions from a convening at Institut Pasteur in Paris in June 2017 aimed at defining practical and informative use cases for serology applications and highlights five programmatic uses for serological assays including: documenting the absence of transmission; stratification of transmission; measuring the effect of interventions; informing a decentralized immediate response; and testing and treating P. vivax hypnozoite carriers., Competing Interests: No competing interests were disclosed.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.